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Thesis abstract 
Multifocal visual evoked potentials (mfVEP) can offer vital information regarding the 
integrity of the visual system. In this thesis, the mfVEP changes in demyelinating 
diseases of the visual pathway were investigated. Four main areas were explored.  First, 
the efficacy of the mfVEP technique compared to full-field pattern-reversal visual 
evoked potential (PVEP) was evaluated in six patients with known pathologies at 
various levels of the visual pathway. The case series demonstrated a potentially higher 
sensitivity of mfVEP compared to conventional PVEPs in detecting lesions affecting 
the peripheral visual fields and horizontal hemi-fields and lesions of the post-chiasmal 
pathway.  
Second, mfVEP evolution in optic neuritis (ON) in the affected and fellow eyes during 
the first year after the attack was analysed. The mfVEP of 87 patients and 25 controls 
were analysed longitudinally and correlated with retinal nerve fibre layer (RNFL) 
thickness. Patients were classified into three groups: those diagnosed with multiple 
sclerosis (MS), and those at high risk (HR) or low risk (LR) for conversion to MS based 
on their magnetic resonance imaging (MRI). The results of this study demonstrated that 
recovery of amplitude and shortening of latency is fastest within the first three months. 
The largest amplitude reduction and longest latency delay of the affected eyes were 
recorded in the MS group. This was accompanied by statistically significant 
deterioration of both parameters in the fellow eyes. MfVEP remained stable in the 
fellow eyes of the LR group. Inter-eye asymmetry analysis was used to minimise the 
bilateral effect of any potential retro-chiasmal lesions and revealed a similar amount of 
amplitude reduction and latency delay in all three groups. RNFL thickness strongly 
correlated with mfVEP amplitude as early as three months after ON (R
2
 = 0.6, 
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p = 0.001). This study indicated that mfVEP amplitude can be used as an early predictor 
of post-ON axonal loss. In addition, the findings suggest that the apparently more 
severe involvement of ON eyes in the MS subgroup may be due to subclinical 
inflammation along the visual pathway. 
The third aim was to analyse the mfVEP latency and waveform changes of the fellow 
eyes of patients with clinically isolated ON and MS-related ON in greater depth by 
evaluating mfVEP traces from individual segments, and to address the possible effect of 
cortical adaptation on latency change. The latency and waveform changes of mfVEP 
traces in fellow eyes of 15 ON patients were analysed and correlated with latency delay 
of the affected eyes. Eight age- and gender-matched controls were also included for 
comparison. The study showed that while there was a slight mfVEP latency change 
between three and 12 months post-attack in the fellow eyes of ON patients with low risk 
of MS that might support the hypothesis of cortical adaptation as the mechanism of its 
delay, the mfVEP latencies remained within the normal range. The significant mfVEP 
latency delay in the fellow eyes of MS patients and the change over time compared to 
clinically isolated ON patients and controls supports the assumption that the changes are 
due to subclinical demyelination in the visual pathway.  
The fourth aim was to test the hypothesis that the latency delay of mfVEP in non-ON 
eyes of MS patients is related to retro-chiasmal demyelinating lesions. Fifty-seven MS 
patients with no history of ON at least in one eye and 25 age- and sex-matched controls 
were tested. Probabilistic tractography was used to reconstruct optic radiation (OR) 
fibres. MS lesion volume on MRI and diffusion tensor imaging (DTI) indices was 
measured. The relationship of the mfVEP latency with OR lesions and DTI indices was 
examined. A significant association was revealed between mfVEP latency delay and 
OR lesion load. There was also a significant correlation between mfVEP latency and 
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OR DTI. The findings of this study support our hypothesis that latency delay of the 
mfVEP in the eyes of MS patients without previous ON is related to retro-chiasmal 
demyelinating lesions.  
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Chapter one: Thesis overview and background 
 
 
 
 
 
 
 
 
 
  
  2 
1.0 Overview 
This chapter is an introduction to the thesis and includes a brief background and review 
of relevant literature. The chapter is divided into three main sections. The first section 
briefly discusses the general aims and rational of this thesis. Section two describes the 
basic anatomy of the visual pathway whereas section three reviews visual evoked 
potentials including multifocal visual evoked potential (mfVEP) with a focus on cortical 
origin of generated signals and visual evoked potential changes reported in various 
visual pathway pathologies. The visual pathway is highly susceptible to multiple 
sclerosis (MS) lesions and therefore the last section briefly reviews MS and discusses 
the involvement of the visual pathway in MS. 
1.1 Aims and rationale of this thesis 
Visual evoked potentials (VEP) can offer vital information regarding the integrity of the 
visual system and provide a general objective measure of visual pathway function. 
Advances in recording techniques such as multifocal technology provide topographical 
measurements of visual function allowing localised damage to be identified. 
This thesis has four main aims to address. The first aim is to assess the comparative 
efficacy of mfVEP and full-field pattern VEP techniques in patients with a known 
pathology at various levels of the visual pathway. The second aim is to evaluate the 
mfVEP evolution after acute optic neuritis (ON) and to examine the pattern of 
amplitude and latency changes in ON eyes and fellow eyes in a large cohort of patients. 
Additionally, the association between mfVEP parameters and long-term axonal loss will 
be examined.  
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The third aim of this thesis is to analyse latency and waveform changes of mfVEP 
traces in the fellow eyes of ON patients. Alteration of VEP in an absence of clinical 
symptoms has been reported in the fellow eye of patients with ON, which has been 
attributed to several factors including subclinical demyelination and cortical adaptation. 
MS patients and patients with normal magnetic resonance imaging (MRI) will be 
examined in an attempt to distinguish the effect of cortical adaptation from the effect of 
demyelinating lesions that may occur within the posterior visual pathway.  
The last aim is to investigate the potential relationship of latency delay of mfVEP with 
optic radiation (OR) lesions in MS patients. The OR lesions will be identified using 
tractography and OR diffusion tensors indices (DTI) will be measured. Evaluating the 
correlation between structural and functional measures of visual pathway integrity will 
provide a better understanding of the nature of their relationship.  
MfVEP is an evolving technology and is starting to find its place in the clinical setting. 
The need for more research to better understand the changes of mfVEP in visual 
pathway disorders is imperative. We believe that the studies included in this thesis will 
shed a light on some new aspects of this potentially important technique.  
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1.2 Background 
1.2.1 The visual pathway 
Visual perception occurs when light stimulus in the surrounding environment converts 
to nerve impulses at the level of photoreceptors, which then reach the brain to be 
processed. The light energy is converted to neuronal signals that are transmitted through 
several layers in the retina to reach the ganglion cells. The axons of the ganglion cells 
form the optic nerve. Signals are carried out from the optic nerve through the optic 
chiasm and optic tract, which is connected to the lateral geniculate body. From there, 
signals reach the visual cortex in the occipital lobe through the optic radiation (Fig 1.1). 
 
Fig 1.1: The visual pathway anatomy. 
Source : http://www.aao.org/theeyeshaveit/anatomy/visual-pathway.cfm 
 
The arrangement and distribution of visual pathway fibres have been extensively 
studied (1-3). Because damage in this pathway could be measured functionally and 
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structurally, understanding the optic fibres pathway will help to recognise lesion 
location based on the visual field defect and the associated functional disturbance.  
This section discusses the anatomy of the visual pathway that is relevant to our 
research.  
Retina 
The retina, which is situated between the choroid and the vitreous, is the site where 
photons are converted into neuronal signals. Although the retina is around 0.4 mm in 
thickness, it has a well-organised structure consisting of ten layers, three of them 
nuclear layers (Fig 1.2) (2). 
 
Fig 1.2: The anatomy of the retina. Source: Remington, L.A. Clinical anatomy of the 
visual system. Elsevier Health Sciences; 2011 
 
The outermost layer is the retinal pigment epithelium, which is a single layer of 
pigmented cells between the neurosensory retina and the choroid. It has several 
functions including light absorption, controlled transport of substances, and 
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phagocytosis (4). The photoreceptor layer contains the outer and the inner segments of 
three types of cone and one type of rod photoreceptors. Cones are responsible for sharp, 
detailed, and colour vision while rods are responsible for vision under dim (scotopic) 
conditions. The highest distribution of cones is at the macula, which is at the central 
part of the retina. On the other hand, the rods have high distribution throughout the 
retina, which declines significantly at the macular area (2). 
The external limiting membrane is between the photoreceptor layer and the outer 
nuclear layer.  Histologically it is adherent junctions between photoreceptors and Müller 
cells which act as a metabolic barrier for some large molecules and therefore it is not 
considered a real membrane. The cell bodies of the photoreceptors form the outer 
nuclear layer. The outer plexiform layer consists of a network of neuronal synapses 
connecting the photoreceptors to bipolar cells and horizontal cells, while the inner 
nuclear layer consists of horizontal, bipolar and amacrine cells. The inner plexiform 
layer contains dendrites of retinal ganglion cells and processes of bipolar and amacrine 
cells (2). 
The ganglion cell layer contains bodies of the ganglion cells, which receive their input 
from bipolar and amacrine cells and are the first cells to produce action potentials. 
There are three main types of ganglion cells (2, 5, 6). The first type is the midget cells, 
which receive direct input from a single bipolar cell and therefore have small receptive 
fields. Their axons form the parvocellular pathway. The second type is the parasol cells, 
which receive their input from diffuse bipolar cells and thus have larger receptive fields. 
They form the magnocellular pathway. The third type is the small bistratified cells, 
which have blue-ON receptive fields and project through the koniocellular pathway. 
Additionally, there are several other different ganglion cell types that have been 
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identified, for example, the melanopsin-containing ganglion cells which are involved in 
non-image forming visual functions and pupillary responses (7, 8). 
The nerve fibre layer (NFL) is comprised of ganglion cell axons, which are generally 
unmyelinated in the retina. The innermost layer is an internal limiting membrane and it 
is formed by the footplates of Müller cells and a basement membrane (9). The outer 
retina receives blood supply from the choroid while the central retinal artery supplies 
the inner retinal layers. 
The optic nerve 
Ganglion cell axons turn 90° to enter the optic disc, where they form the optic nerve. 
The optic disc is supplied by a ring of branches from the short ciliary arteries called the 
circle of Zinn. Peripapillary arteries also contribute to the optic disc blood supply.  The 
optic nerve consists of 2.2 million fibres with different sizes of diameter, ranging from 
0.7 μm to 10 μm. Smaller fibres serve the central vision while larger ones come from 
the peripheral retina (10). The macular fibres are deep in the centre of the optic nerve 
while the fibres of the peripheral retina are more superficial.  
The length of the optic nerve is around 6 cm and can be divided anatomically into four 
segments: intraocular ( 0.7 to 1 mm), intraorbital (30 mm), intracanalicular ( 6 to10 
mm), and intracranial ( 10 to 16 mm). The lamina cribrosa divides the intraocular 
part into prelaminar and laminar sections (2). It is important to note that this part 
of the nerve is not myelinated. Oligodendrocytes are responsible for the 
myelination of nerves and it is believed that the lamina cribrosa acts as a barrier 
preventing them from myelinating the intraocular section of the optic nerve (3). 
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Beyond the lamina cribrosa the optic nerve is myelinated and surrounded by a 
duaral sheath and cerebrospinal fluid. The extraocular muscles surround the optic 
nerve in the orbit. The optic nerve sheet is adherent to the superior and medial 
rectus muscle, hence the pain with eye movement when the optic nerve is 
inflamed in cases such as ON. The ophthalmic artery is the first branch from the 
internal carotid artery and it forms the main blood supply for intraorbital and 
intracanalicular division of the optic nerve. The ophthalmic artery passes through 
the dural sheath of the optic nerve in the intracanalicular section. The intracranial 
optic nerve division is supplied by branches from the ophthalmic, interior 
cerebral, anterior communicating, and internal carotid arteries. 
Optic chiasm  
Ninety percent of the optic nerve fibres from both sides join in the optic chiasm while 
the remaining ten percent of fibres project to areas controlling pupillary responses (3). 
In the optic chiasm, the medial fibres partially cross (decussate) to terminate in the 
opposite side of the brain, representing about 53% of optic nerve fibres. Some nasal 
fibres may loop either into the end part of the opposite optic nerve (anterior knees of 
Wilbrand) or into the optic tract of the same side before crossing (posterior knees of 
Wilbrand). The temporal optic nerve fibres run directly through the chiasm to the optic 
tract on the same side. Nasal optic nerve fibres cross to the opposite side at the optic 
chiasm and terminate at the opposite side of the brain.  
The optic chiasm has a rectangular shape, measuring 15 mm by 8 mm with a thickness 
of 4 mm. Similar to the optic nerve, the optic chiasm is surrounded by a dural sheath 
and cerebrospinal fluid (2).  
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Above the optic chiasm is the third ventricle and around 1 cm below it is the pituitary 
gland, resting in a small cavity called the sella turcica. The position of the optic chiasm 
above the sella turcica varies among individuals. Around 75% of the population has the 
chiasm directly above it, while 15% have the gland displaced posteriorly (prefixed) 
because of shorter optic nerves and 10% have it displaced anteriorly (postfixed) because 
the optic nerves are long and the gland lies just below the anterior part of the chiasm (2, 
3). The optic chiasm lies within the circle of Willis from where it receives its blood 
supply via capillary beds from the anterior cerebral, anterior communicating, internal 
carotid, posterior cerebral, and posterior communicating arteries.  
The optic tract 
The optic tract originates from the posterior lateral side of the optic chiasm and ends at 
the lateral geniculate nucleus, where the fibres of the ganglion cells terminate. In the 
optic tract, fibres from the inferior peripheral retina run laterally while superior 
peripheral fibres run medially and the macular fibres in between. The optic tract 
measures around 5.1 mm in length and 3.5 mm in thickness (3). The main blood supply 
of the optic tract comes from the anterior choroidal artery, which originates from the 
internal carotid artery.   
Lateral geniculate nucleus  
The lateral geniculate nucleus (LGN) is located in the dorsolateral part of the thalamus. 
Retinal fibres end at the LGN and fibres from the LGN project to the visual cortex as 
the optic radiation. The LGN is composed of six layers where layers one and two 
receive information from the magnocellular pathway and layers three to six receive 
input from the parvocellular pathway. Those two pathways are anatomically and 
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functionally distinct (2). While the magnocellualar pathway is responsible for 
processing motion and high flicker perception, the parvocullelar pathway is mainly in 
charge of pattern and colour information analysis (11).  
Because the LGN receives input from both cortex and subcortical centres, it has a very 
complex role in the visual process and acts as a selective regulator of visual information 
flow to the visual cortex (3). The LGN receives blood supply from branches of the 
posterior cerebral artery. 
Optic radiation (OR) 
The OR is composed of LGN fibres that run deep in the white matter of the cerebral 
hemispheres. Anatomically, the optic radiation is divided into three sections. The 
anterior section passes laterally to the inferior horn of the lateral ventricle. This section 
receives blood supply from the anterior choroidal artery and the middle cerebral artery. 
The second section is the middle one, through which OR fibres run laterally to the 
ventricles. It is supplied by the deep optic branch of the middle cerebral artery. The 
third section is the posterior part of the OR, which is supplied by branches of the 
posterior cerebral artery and the middle cerebral artery. Fibres from the inferior retina 
pass through the temporal lobe while fibres from the superior retina pass through the 
parietal lobe (12). Macular fibres are usually located in between the superior and 
inferior fibres (2). The OR fibres terminate at the primary visual cortex. 
Primary visual cortex  
The primary visual cortex (V1) extends from the posterior pole onto the medial surface 
of the occipital lobe. It is supplied mainly by the calcarine branch of the posterior 
cerebral artery and receives some contribution from the middle cerebral artery (2, 3).  
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The calcarine fissure divides the primary visual cortex into the upper division (cuneus 
gyrus) and lower division (lingual gyrus). The upper division receives fibres from the 
superior part of the optic radiation while the lower division receives fibres from the 
inferior part of the optic radiation. V1 has six main neuronal layers. The optic radiation 
axons terminate in the fourth layer, known also as the lamina granularis interna, which 
is further divided into 4A, 4B, and 4C. The magnocellular axons terminate in the upper 
half of 4C (also called 4Cα) while the parvocellular axons terminate in the lower half 
(4Cβ). V1 layers have rich interlayer connections and projections to other areas in the 
cortex and to subcortical areas. 
Macular fibres project onto the most posterior part of V1 with the superior macular 
fibres projected onto the cuneus gyrus and the inferior macular fibres projected onto 
the linqual gyrus. Although the macular area at the retina is relatively small, macular 
fibres have a large representation at the primary visual cortex (Figure 1.3). Around 50-
60% of V1 is devoted to the central 10
ο 
of the retina (3, 13). 
 
 
Fig. 1.3: Left image: The medial side of the left occipital cortex showing the 
representation of the right visual field. The dotted lines represent eccentricity from the 
fovea in degrees. Right image: The layout map of the right visual hemi-field. The 
vertical lines indicate eccentricity in degrees. The dark spot corresponds to the right 
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blind spot. Adapted from Horton JC. Ocular integration in the human visual cortex. 
Can J Ophthalmol 2006;41(5):584-93 
 
In 1977, Hubel and Wiesel described a modular organisation of V1 (14). They 
proposed that the cortex is composed of modules with a set of orientation columns of 
cells crossed by ocular dominance columns and colour sensitivity blobs. Cortical 
cells are organised in specific horizontal and vertical patterns to analyse contour and 
depth perception accurately (3, 14, 15). 
One of the early attempts to study the retinotopic organisation in the visual cortex was 
by a Japanese ophthalmologist named Tatsuii Inouye in 1905 (16). Years later, Gordon 
Holmes proposed a map of the visual field representation in the human visual cortex 
based on the visual field loss resulting from gunshot wounds during World War I (17). 
Accordingly, it was demonstrated that the upper and lower visual fields are represented 
in the lower and the upper banks of the contralateral calcarine fissure respectively.  
With the advances in MRI, Horton and Hoyt reassessed Holmes’ map and concluded 
that it provides an accurate estimate of the retinal projections to the visual cortex but 
that it underestimated the cortical magnification of the central vision, and proposed a 
revised map (Fig. 1.3) (13, 18). 
The extra-striate cortex includes several functional areas within the visual cortex that 
are involved in processing of visual information. Brodmann area 18, also called V2, 
is adjacent to V1 and projects to other extra-striate areas. V3 receives input from both 
V1 and V2 and has a role in depth perception, motion and direction. V4 appears to 
receive input from the parvocellular pathway and has a role in colour perception. V5 
receives input from V1 and directly from the magnocellular pathway and thus plays a 
  13 
role in processing movement and direction of visual stimuli. V6 plays a role in facial 
recognition and saccadic movements (3). This brief anatomy review is clearly 
simplified but the complex details of the primary visual cortex function are beyond 
the scope of this thesis. 
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1.2.2 Visual evoked potentials (VEP) in the assessment of the 
visual pathway 
VEP background  
VEP is an electrical response recorded mainly from the visual cortex in response to light 
stimuli. It was first introduced in the 1930s and its role has evolved over the years (19). 
In 1961, Ciganek was the first to describe an electroencephalography (EEG) response to 
a flashlight stimulus in humans, followed by one of the earliest clinical studies of VEP 
reported by Halliday and colleagues on patients with optic neuritis (20, 21)  
VEP provides an objective and reproducible measure of visual function and continues to 
have an imperative complementary role to other tests that provide information on the 
structure of the visual system such as MRI and optical coherence tomography (OCT).  
The recording of VEP is performed using occipital mounted electrodes with, typically, 
monocular stimulation. Several forms of visual stimulus can be used to generate a VEP. 
The most common stimuli used are flash visual evoked potential (fVEP), pattern-onset 
VEP and reversing black and white checkerboard pattern (PVEP).  Because of fVEP’s 
high inter-subject variability and low sensitivity, PVEP is preferred in most clinical 
setting. fVEP is frequently used in infants, uncooperative patients or if significant media 
opacity is present. The pattern-onset VEP is preferred in patients with fixation 
instability such as syntagms since the PVEP is severely reduced in those patients due to 
the effect of retinal image motion on the stimulus efficiency (22, 23). 
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The testing technique for these stimulus conditions has been standardised by the 
International Society of Clinical Electrophysiology of Vision (ISCEV) to reach a better 
consistency of results between different electrophysiology laboratories (24).  
The PVEP waveform is triphasic with a prominent positive peak (P100) at around 100 
ms, an earlier negative peak at around 75 ms, and a late negative peak at around 135 ms 
after stimulation (Fig 1.4). The amplitude of the P100 reflects the number of functional 
afferent axons reaching the cortex. The implicit time (latency) is believed to reflect the 
degree of demyelination. An abnormal VEP response indicates a functional disturbance 
in the afferent visual pathway and occasionally conventional VEP may provide some 
information on the location of the lesion (25). For example, based on the neuroanatomy 
of the visual system, a unilateral VEP abnormality implies an abnormality in the 
anterior optic pathway. Localisation is less likely when the delay is bilateral.   
 
Fig 1.4: Normal waveform of a standard PVEP. Arrows showing first negative peak 
(N75), positive peak (P100) and a late negative peak (N135)  
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Cortical sources of VEP  
The retinotopic organisation in V1 (discussed previously in 1.2.1) indicates that the 
upper visual hemi-field is mapped in lower banks while the lower visual hemi-field is 
mapped in the upper banks of the calcarine fissure. Therefore, visual stimulation of the 
upper hemi-field will generate evoked potentials that are opposite in polarity to that 
generated by the hemi-field stimulus. The polarity of the VEP would not change in 
response to changing stimulus position for VEPs generated from other visual areas. As a 
result, several studies have shown that the first major component of PVEP reverses in 
polarity when the stimulus position is changed between the upper and lower visual 
fields. Therefore, it arises primarily in V1. In contrast, the dominant later components 
seem to be generated in multiple extrastriate areas (25-28). In the multifocal recording 
technique, as discussed in the following chapters, the stimulation and recording 
conditions are different. This results in a different waveform generated mainly from V1 
with less extrastriate contribution (29). Fortune and Hood suggested that the fast 
stimulation sequence used in the multifocal technique reduces the contribution of 
extrastriate areas and results in a waveform that is largely generated from V1 (30).  
VEP in optic neuritis and multiple sclerosis 
One of the earliest reports of VEP changes in patients with ON was in the early 1970s 
when Halliday and colleagues compared 19 cases of ON with healthy controls and 
reported a significant latency delay in the ON group, which persisted despite 
improvement in visual acuity (21).  Since then, many studies have confirmed this 
observation (25, 31-33). During early stages of ON, PVEP shows reduced amplitudes 
and delayed latencies with amplitudes generally returning to normal or near normal 
after a few weeks. Severe inflammation in acute ON may result in reversible conduction 
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block with an extinguished VEP waveform. These changes in VEP are often 
accompanied by gadolinium enhancement of the optic nerve lesion on MRI. 
Persistent amplitude reduction has been associated with reduced visual acuity, 
decreased retinal nerve fibre layer thickness on OCT, and optic nerve atrophy (34, 35). 
A more detailed background on ON changes is discussed in chapter three. 
Although the rapid developments in MRI may seem to overshadow the role of VEP in 
the diagnosis and monitoring of MS patients, VEP studies still add a substantial insight 
into the pathophysiology of this complex disease. There is strong evidence that the 
majority of MS patients without visual involvement would have an abnormal VEP (36, 
37).  
There have been several attempts to assess whether MS affects the function of the 
magnocellular or parvocellular visual pathway. However, the results provided by many 
studies in this area were inconsistent. Some studies suggested that the magnocellular 
pathway is more commonly affected in MS, while others claimed that the parvocellular 
pathway is more sensitive to MS injury (25, 38, 39).  There is no straightforward 
explanation for this contradiction. However, difference in disease subtype and duration 
could affect the results. For instance, it has been suggested that magnocellular 
involvement occurs early in the disease course while profound parvocellular pathway 
involvement may be evident in advanced cases of MS (25).  
The presence of subclinical VEP abnormality in MS patients is in agreement with brain 
imaging and histopathological studies that provide evidence of disease activity even 
during the remission phase (40). In addition, VEP has been suggested as a surrogate 
marker to predict MS patients with high risk for long-term disability due to good 
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correlation between evoked potentials and disability scores observed in MS and has 
been used as an outcome in recent MS therapeutic trails (41, 42). 
Multifocal visual evoked potentials (mfVEP) as an objective measure 
of visual pathway function 
While VEP frequently detects optic nerve diseases, it is less sensitive in detecting or 
localising postchiasmal pathology (43). The full-field VEP response is dominated by the 
central vision due to cortical overrepresentation of the macular area. Furthermore, since 
the full-field VEP waveform is a vector sum of numerous differently oriented dipoles, it 
is prone to unpredictable changes, including cancellation, depending on the part of the 
nerve or visual field affected, which may affect the clinical usefulness of the full-field 
VEP. As a result, the need for an objective topographic test of optic nerve function with 
measurement of amplitudes and latencies from locally derived VEP responses in 
numerous small areas of the visual field has been recognised for more than two decades.  
Attempts to record VEP from partial stimulation of the visual field, including the 
stimulation of hemi-fields, quadri-fields and segments, have been used in clinical 
pratice particularly by neurologists. Although those techniques have improved the 
detection of peripheral visual field defects, they were often time-limited by serial 
stimulation and significant lower responses from the upper visual hemi-fields (44, 45). 
In the early 1990s, Baseler and colleagues reported one of the earliest attempts to 
eliminate PVEP limitation by using a multi-input recording technique. They were able 
to record responses from multiple field locations simultaneously rather than a summed 
overall response (46). Recent technical refinements of mfVEP and electrode placement 
have significantly improved the quality of recordings and decreased inter-subject 
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variability, which has resulted in improved performance in cases of small or peripheral 
deficits (47, 48). It allows for a better assessment of the optic nerve function via 
stimulation of 58 different regions of the central 24° radius of the visual field. The 
checkerboard pattern used for stimulation is scaled based on cortical magnification. For 
instance, the foveal sectors are about 1° wide, while the peripheral sectors exceed 7°. 
This scaling results in stimulation of approximately equal cortical areas and therefore 
overcomes macular overrepresentation (47, 49).   
MfVEP visual field assessment and analysis 
Amplitude assessment 
MfVEP also has an advantage over PVEP in providing an idea of the size and depth of a 
visual field defect. It should be noted, however, that the mfVEP arrays are not an 
objective version of visual field perimetry maps such as the Humphrey visual field 
(HVF) because the visual field is stimulated differently by the two techniques (29). For 
example, the stimuli used in the HVF test have the same size and are spaced equally 
while the mfVEP stimuli vary in size and spacing since they are cortically scaled (47). 
Several studies have shown a good agreement between the probability plots for the two 
tests (47, 50-53). To minimise the false positive defects on mfVEP plots, an amplitude 
cluster approach similar to the one used to define a defect on HVF was suggested (52, 
54, 55). Goldberg and colleagues suggested that a local area of the visual field defect 
(scotoma) is present when there is a cluster of three adjacent zones with a p < 0.05 with 
at least one with a p < 0.02 (52).  Hood and colleagues suggested slightly modified 
criteria with any two points with p < 0.01 or three points with p < 0.05 with at least one 
of them with p < 0.01 (54).  Hemamalini Arvind and colleagues define a visual field 
defect on mfVEP as a cluster of three or more abnormal points, with at least two points 
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depressed by p < 0.02. Defects immediately above and below the blind spot were not 
considered part of the scotoma (55). These criteria ensure that results are valid and 
reliable (56). 
Latency delay assessment  
Measuring mfVEP latency has been challenging because of the small signal to noise 
ratio (SNR) and trace waveform variability. The latency of mfVEP sectors can be 
grouped and measured manually (57). This approach is subjective and time consuming. 
Moreover, sector grouping may reduce the spiral resolution of mfVEP. 
Few automated methods have been suggested to calculate the latency of mfVEP traces 
(58-60). Hood and colleagues proposed a template method, which involved comparing 
the patient mfVEP traces to a template obtained by averaging the mfVEP response of 
100 normal subjects using a cross-correlation (58). This method has some limitations 
such as dealing with traces with reverse polarity and the need for a large normal 
database. Thie and colleagues have suggested another method to measure the latency 
using cross-correlation with second order Gaussian wavelet kernels (60). The 
limitations of this method include dealing with the polarity of peaks and treating traces 
with “double humps” as it is uncertain whether one of the peaks in double humps traces 
is an artefact or a wide major peak that was pulled by an artefact (60). Advanced 
algorithms are under development to tackle some of these issues and improve the 
accuracy of latency measurement and progression (61).  Another approach is to measure 
the latency of mfVEP by identifying waveform characteristics such as the start of 
response, which is the first response that crosses the 95th percentile of noise, and the 
first or second major peak (Fig 1.5). Sriram and colleagues have demonstrated less 
variability of the first and second major peaks compared to the start of response (62). 
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This indicates that the first and second major peaks are less dependent on noise levels 
and more reliable in measuring mfVEP latency. 
                
Fig 1.5: MfVEP waveform illustrating the three locations for potential latency 
measurement 
A commonly used approach is described by Klistorner and colleagues which involves 
an algorithm to select the channel with the largest peak-to-peak amplitude for each 
segment with the second large peak used to measure the timing of latency (59, 63). This 
approached is used in the studies included in this thesis except for one study where 
latency was measured manually as described in the methodology section of chapter 
four.  
A large bulk of mfVEP research has been done on the detection of glaucoma and 
monitoring its progression (29, 50, 55, 64). MfVEP showed promising results especially 
in patients with unreliable subjective visual fields. Blue-on-yellow mfVEP was 
suggested as a potential tool to detect pre-perimertric functional loss in patients with 
glaucomatous optic discs because of the stimulation of the blue-yellow pathway, which 
has a lower functional redundancy and a higher sensitivity to neuronal loss (55, 65). 
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However, it has been emphasised that the mfVEP test works as an adjunct for subjective 
visual field testing rather than replacing it. 
The ability of mfVEP to provide valid measurements is essential in order to utilise its 
results. Both the sensitivity and specificity of mfVEP in detecting visual pathway 
defects are high (66-68). MfVEP demonstrated a higher performance in comparison to 
HVF and PVEP in a number of neuro-ophthalmological conditions. In ON, mfVEP was 
more sensitive than HVF and OCT, detecting up to 89% of cases in comparison to only 
72% by HVF and 69% by OCT (66).  Similar results were found when mfVEP was 
compared to full-field VEP in patients with typical ON. By using amplitude and latency 
asymmetry of mfVEP, defects were identified in 89% of cases in comparison to 73% 
using full-field VEP (67). MfVEP has a sensitivity of 95% and a specificity of 89% in 
detecting glaucomatous defects (50). Likewise, results from compressive optic 
neuropathies demonstrated high agreement between mfVEP and HVF (53). 
Test-retest reliability is another important aspect in any newly introduced test. Several 
studies reported a good repeatability of mfVEP among normal individuals and 
glaucoma patients, which was comparable to and in some studies even better than HVF 
(56, 69-71).    
As any other test, mfVEP has some limitations. One of the earliest limitations 
recognised was high inter-subject variability, which might affect the interpretation of 
test results (46). The main cause of variability in response between individuals is their 
cortical anatomy. Since the cortex is folded differently in every individual, the position 
of the primary visual area and its position in relation to the position of recording 
electrodes can result in noticeably different mfVEP responses (48, 72, 73). Additionally, 
differences in the conductivity of tissues such as skin thickness, the amount of 
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underlying fat, general brain activity, age and sex all have a role in increasing inter-
subject variability (74). Recent developments, particularly EEG-based normalisation, 
have significantly improved the quality of recordings and decreased inter-subject 
variability allowing a gender- and sex-normative data base to be used by mfVEP 
software packages to create a grading scale with probability maps (47, 52, 74).  
MfVEP responses from eyes of the same individual are usually very similar due to the 
fact that they project to the same cortical region and, hence, are not affected by cortical 
folding. Therefore, in cases of single eye involvement, an interocular comparison 
provides accurate and early detection of localised defects within the visual pathway 
(48).  Technical limitations such as eyelid position, refractive errors and poor fixation 
may all influence the results of recordings and increase noise levels and should be taken 
into account and minimised if possible when recording mfVEP (49).   
MfVEP in demyelinating disorders 
MfVEP changes in demyelinating disorders have been evaluated in several studies (37, 
63, 66-68, 75-78).  The reduction of mfVEP amplitude during acute ON has been 
observed and was mainly attributed to acute inflammation and conduction block and, as 
in conventional VEP, mfVEP often demonstrated persistence of abnormal latency 
measurements in patients after visual acuity fully recovered (63).  Hood and colleagues 
have demonstrated the ability of mfVEP to identify local defects following full recovery 
of visual acuity with amplitude reduction documented in areas of depressed visual 
sensitivity confirmed by HVF (79). Because of its ability to detect small and peripheral 
defects, mfVEP provided an evidence of heterogeneity of functional defects in patients 
with ON and allowed for better monitoring of functional recovery (59, 79). MfVEP 
amplitude has been shown to have a good topographic agreement with the retinal nerve 
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fibres layer (RNFL) thickness in corresponding areas, which provide an additional 
support for the role of mfVEP in disease monitoring (75). In addition, Klistorner and 
colleagues previously demonstrated that the degree of initial inflammatory 
demyelination of optic nerve is potentially a vital factor influencing the total long-term 
remyelination process (80). Further details on ON are discussed in chapter three. The 
following section provides a brief introduction to MS including its pathophysiology and 
the visual pathway involvement in this disorder.  
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1.2.3 Multiple sclerosis (MS) 
Background 
 MS is a chronic autoimmune disease affecting the central nervous system (CNS) which 
is characterize by loss of myelin and nerve fibre degeneration (81). The early 
description of a case suggestive of MS dates back to the 14
th
 century when partially 
recovered episodic neurological weakness and progressive neurological deterioration 
were described and documented (82). Jean-Martin Charcot was the first to correlate the 
clinical and the pathological features of this disorder in late 19
th 
century (83). 
MS is the commonest demyelinating disease causing disability in young adults with 
more than two million people diagnosed worldwide. It typically affects individuals from 
age 20 to 40, but occasionally it can present in children and late middle-aged adults. 
Females are more frequently affected than males (with a ratio of 2:1). Common clinical 
findings in MS are limb spasticity, sensory disturbance, ataxia, bladder dysfunction and 
ON. 
According to the Australian Bureau of Statistics, the prevalence of MS in Australia is 
estimated to be 95.2 per 100,000 persons (84). However, the prevalence of this disorder 
varies from state to state. Several factors may influence this difference including 
latitude and demographic factors. In low latitude areas such as Queensland the 
prevalence of MS was estimated to be as low as 11 per 100,000 people while the 
prevalence increases in areas of higher latitude such as Tasmania (85). The explanation 
for this pattern of disease distribution is still not fully understood.  
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There are more than 23,000 people in Australia living with MS where about half of 
them have a severe disability (84). Because MS generally affects people in their mid-
thirties, the long-term financial and social burden of the disease is substantial. 
MS diagnosis 
The early manifestation of MS usually involves neurological dysfunction (attack) 
lasting at least 24 hours. The dysfunction has to have a CNS origin and occurs in the 
absence of fever, infection or metabolic disturbance. MS is diagnosed based on clinical 
and para-clinical evidence of inflammatory demyelination of CNS after ruling out other 
possible conditions.  
In 1983, Poser and colleagues proposed a scheme for MS diagnosis based on clinical, 
MRI, VEP, and cerebrospinal fluid (CSF) immunoglobulin abnormalities (86). Poser’s 
criteria divided patients into definite, probable, or possible MS. Since then, the role of 
MRI in the diagnosis of MS has been increasingly recognised. In 2001, the International 
Panel on the Diagnosis of Multiple Sclerosis proposed updated criteria for the diagnosis 
of MS (87). The aim was to have updated guidelines for the diagnosis of MS that could 
be useful to neurologists during their routine practice. These criteria are known as the 
“McDonald criteria” and named after the chair of that panel, Dr W. Ian McDonald. The 
latest revision of the McDonald criteria was released in 2011 (88). The revision 
included new evidence and refined some of the original definitions.  
An essential criterion to diagnose MS is evidence of dissemination of lesions in both 
space and time, which means evidence of involvement of at least two areas of the CNS 
at least one month apart. The evidence is collected through a medical history, careful 
neurological examination and para-clinical findings such as MRI, CSF and VEP.   
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MS clinical course 
The clinical course of the disease is quite variable. However, certain patterns have been 
recognised and MS generally can be divided in to four main subtypes: relapsing 
remitting, primary progressive, secondary progressive, and progressive relapsing (89).  
Relapsing remitting 
Relapsing remitting MS (RRMS) is characterised by episodes of acute neurological 
attack such as optic neuritis, ataxia, or limb weakness followed by a variable amount of 
recovery with no disease progression between attacks. Up to 90% of patients will 
present with this form of the disease.  
Primary progressive  
Patients with this subtype will suffer from gradual deterioration of neurological signs 
and symptoms with minimal improvement but no well-defined relapses. Around 10% of 
patients will present with primary progressive MS (PPMS). This subtype is the most 
resistant to MS-modifying treatments. 
Secondary progressive 
Half the patients with RRMS will develop secondary progressive MS (SPMS) at a later 
stage with progressive deterioration and occasional relapses. Disease-modifying agents 
can delay this progression in many patients with RRMS if treatment is used early in the 
course of the disease. 
 
 
  28 
Progressive relapsing 
In this rare subgroup, the progression of MS is evident from onset and associated with 
distinct relapses with or without recovery. This pattern is evident in less than 5% of MS 
patients. Unfortunately there are still no biological or immunological markers to help in 
early recognition of MS subtypes to improve prognostic ability and allow for better use 
of various disease-modifying agents.  
MS pathophysiology 
The basic pathology of MS was described in the late 19
th
 century as a chronic 
inflammatory demyelinating disorder characterised by the presence of demyelinating 
plaques (83). It has become apparent over the past decade that MS pathogenesis is far 
more complicated than predicted previously with much more widespread damage of the 
brain and spinal cord, including white and grey matter, particularly at late stages of the 
disease. Although demyelination is still considered a distinctive histopathological 
feature, in recent years the contribution of axonal damage to functional disability has 
been increasingly recognised (90, 91). The loss of white matter integrity remains a key 
area of MS pathophysiology.  
Axons in CNS are insulated by a material known as myelin, which assists in the fast 
conduction of action potentials along nerve axons. Oligodendrocytes are the cells 
responsible for synthesising and maintaining myelin integrity. These cells and other 
neural cells in CNS are generally protected from inflammatory cells circulating in the 
blood by the blood brain barrier (BBB). The BBB is composed of endothelial cells, 
which line the walls of blood vessels in the central nervous system. Compared to 
normal endothelial cells, the cells lining the BBB are connected by occludin and 
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claudin, which form tight junctions in order to create a barrier to keep out larger 
molecules such as proteins. In order to pass through, molecules must be taken in by 
transport proteins or an alteration in the BBB’s permeability must occur. Therefore, 
normally most immune cells are effectively separated from the CNS by this barrier. 
Immune cells are essential for detecting and eliminating abnormal cells, whether 
infected or neoplastic, and under normal circumstances they would not attack normal 
tissues.  
It is believed that in MS this harmony is disturbed and T lymphocytes, B lymphocytes 
and plasma cells infiltrate the white matter in the brain and spinal cord, producing 
inflammation, demyelination and axonal damage (92).   
Cell-mediated myelin damage and oligodendrocyte death  
T lymphocytes 
An important immune cell in the pathogenesis of MS is the T lymphocyte. T helper 
cells, also known as CD4+ T cells because they express the CD4 glycoprotein on their 
surface, and cytotoxic T cells, known as CD8+ T cells since they express the CD8 
glycoprotein, reach the CNS either due to the corrupted BBB or due to the fact that 
activated T cells are allowed to patrol the brain parenchyma. Both mechanisms may 
also occur simultaneously. It is likely that the T lymphocytes are first activated in the 
periphery and then migrate into the CNS, where they become reactivated against target 
antigens, resulting in cytotoxic damage (93). 
It is believed that myelin components act as an antigen for T lymphocytes resulting in 
myelin sheath damage and impaired nerve conduction (94).  
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The exact role and the extent of the damage related to CD8+ and CD4+ T cells are not 
yet well defined.  It is recognised that CD4+ T cells play a major role in this disease 
(95). This is supported by the fact that certain human leukocyte antigen (HLA) class II 
molecules, that have a role as antigen-presenting molecules to pathogenic CD4+ T cells, 
are a strong genetic risk factor for MS. 
Furthermore, there is mounting evidence on CD8+ T cells involvement in the 
pathogenesis of MS. CD8+ T cells were present at the lesion edge as well as 
perivascular regions in animal models of MS (94). Cabarrocas and colleagues have 
shown that activated CD8+ T cells travel freely into the CNS and induce inflammation 
and tissue damage without the need of CD4+ T cell help (96). Therefore, it is likely that 
CD4+ T cells and CD8+ T cells are equally important in MS pathogenesis.  
Humoral-immune-mediated myelin damage and oligodendrocyte death 
B lymphocytes 
While the involvement of antibodies in the pathogenesis of multiple sclerosis has been 
long suspected, the role of B cell lymphocytes has been increasingly recognised. There 
is evidence for B cell clonal expansion in the CSF of the majority of clinically isolated 
syndrome patients and it was suggested that antibody to myelin proteins may contribute 
to loss of myelin (97, 98). However, the understanding of the precise function of B cells 
in this disease is still evolving. 
Neuro-degeneration  
Traditionally, it was believed that the prominent early manifestation of the disease is 
mainly caused by demyelination due to inflammatory processes and that 
neurodegeneration is just a consequence of that, appearing in the later stages of the 
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disease. There is cumulative evidence from studies on histopathology as well as brain 
imaging challenging this view and demonstrating that neurodegenerative changes are an 
early pathological feature in MS (99).  
An additional issue of debate is whether demyelination is a vital requirement for axonal 
loss or both conditions appear independently. Axon loss might be acute, caused by the 
effects of inflammation, or chronic, caused by insidious inflammation or lack of trophic 
support from myelin. Both immunologically mediated and non-immunological 
processes have been suggested as mechanisms of neurodegeneration in MS including 
diffuse microglial activation, glutamate excitotoxicity, calcium influx, mitochondrial 
collapse and damage from acute cytokine release (99). 
Post-mortem evidence suggests  that  axonal degeneration does not  only take  place in 
the  context  of acute lesions , but continues  to occur  during  the later  stages  of the  
disease  when  acute  inflammatory episodes are generally absent (100).  One potential 
explanation for ongoing axonal degeneration in the absence of obvious inflammation is 
that the absence of myelin sheaths leads to a lack of axonal support that ultimately 
results in axonal degeneration (101). Persisting diffuse inflammation may also 
contribute to axonal loss. 
Possible antigens involved in MS 
There has been substantial research to identify relevant antigens in MS with the greatest 
focus on myelin proteins (102). Non-myelin antigens such as the α-B crystallin protein 
have also been suggested as potential antigens (103). However, it is possible that other 
antigens which have not yet been identified, could contribute to the autoimmune 
process in MS (97). 
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Genetic predisposition and environmental factors  
Predisposition to MS involves a complex interaction between genetic and 
environmental factors. The genetic influence in MS was suggested due to familial 
clustering of cases and the high incidence in some ethnic populations, such as groups of 
northern European origin (104). MS nowadays is considered a polygenic disorder even 
though greater numbers of MS patients do not have an affected family member.  
Genetic associations with major histocompatibility complex class I alleles have been 
recognised in several studies. Furthermore, patients with HLA alleles such as HLA-A3 
and HLA-DR2 may have an increased risk of developing MS. Some studies have 
suggested that HLA-DR2 is an independent risk factor for MS, proposing a relative risk 
of 4 (105, 106).  
Several environmental factors, including place of residence, infections (such as Epstein-
Barr virus), lower vitamin D levels and lack of sun exposure, have long been assumed 
to potentially play a role in and increase the risk of MS development (107).  
Visual pathway involvement in MS  
The visual pathway is highly susceptible to inflammatory demyelination injury with 
more than a third of MS patients having some kind of visual impairment (108).  
Involvement of the optic nerve is common in MS and ON occurs in 50-70% of patients 
during the course of their disease. 15-20% of patients present with ON as their first 
manifestation of MS (109, 110). MS patients without ON often demonstrate lower 
visual function including low contrast, visual acuity and colour sensitivity testing when 
compared with controls (111). In addition, reduced RNFL thickness has been 
documented in MS patients without a clinical history of ON. The optic chiasm and post-
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chiasmal involvement is common as well. Evidence of inflammatory demyelinating 
lesions in the posterior visual pathway has been reported in 70-80% of MS patients 
although the majority of them are clinically asymptomatic (36, 112). The visual 
pathway involvement in MS is discussed further in chapter three, four and five. 
The following chapter elaborates further on the rationale of choosing mfVEP over full-
field PVEP by evaluating both techniques in several cases with different visual pathway 
disorders. 
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Chapter two: Assessment of mfVEP and PVEP changes in 
patients with visual pathway disorders: a case series 
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2.0 Overview 
In this chapter both PVEP and mfVEP are used to assess comparative efficacy of the 
techniques in detecting visual field defects in patients with a known visual pathway 
pathology where other tests such as MRI were used to establish diagnosis. This chapter 
consists of four sections. The first section is an introduction and a review of 
comparative studies on mfVEP and PVEP. The second section includes aims and 
methodology used in the current study. Section three describes the participants’ clinical 
and para-clinical findings and reports the results of mfVEP and PVEP. Section four 
includes a discussion on the relative utility of mfVEP in clinical setting compared to the 
conventional pattern reversal technique. 
2.1 Introduction 
Visual pathway disorders can be diagnosed by clinical evaluation and imaging. 
However, if subjective tests such as visual acuity, visual field analysis and color vision 
assessment are inconclusive or not explained by clinical findings, objective 
investigations such as visual evoked potentials may be of use. 
The VEP has been used in the diagnosis of various neuro-ophthalmological diseases for 
many years. As has been discussed in the previous chapter, it is known that the upper 
retina (lower visual field) projects to the upper bank of the sulcus calcarinus (cuneus 
gyrus), while the lower retina (upper visual field) projects to lower bank of the sulcus 
calcarinus (lingual gyrus). Since both banks are facing each other, the polarity of the 
cortical dipoles from the lower and upper hemi-fields is almost opposite. Since the full-
field PVEP is a vector sum of numerous differently oriented dipoles, the waveform of 
the full-field PVEP is prone to cancellation and distortion (47, 113). Furthermore, 
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because of cortical over-representation of the central macula region, the full-field VEP 
response is greatly dependent on the function of that area (114, 115).  Up to 65% of the 
VEP response is produced by stimulation of the central two degrees of the visual field 
(116) and, as a result, a lesion localised in the periphery of the visual field could easily 
be missed.  
MfVEP, on the other hand, enables simultaneous recording from multiple regions of the 
visual field, allowing assessment of a much larger cross-sectional area of the optic nerve 
and, therefore, more accurate functional evaluation of the visual pathway (47). Such an 
objective visual field topographic map may have useful applications in clinical practice.   
Currently the mfVEP has been predominantly used in the assessment of patients with 
glaucoma and optic neuritis and has been shown to have a sensitivity of more than 92% 
and specificity above 90% in detecting visual field defects (68, 117). However, 
relatively few studies have targeted other visual pathway disorders (53, 118-120). 
Furthermore, although there have been some studies comparing mfVEP with 
conventional VEP predominantly in the setting of optic neuritis and glaucoma (67, 68, 
121). Grippo and colleagues studied the effect of glaucoma on latency delay measured 
by both PVEP and mfVEP. Both tests agreed in results and showed only modest latency 
delay. Klistorner and colleagues have compared mfVEP and full field PVEP in the 
sitting of ON and reported a good agreement in amplitude and latency between the two 
tests. In addition, they have shown that mfVEP allowed independent assessment of 
multiple areas simultaneously by including information from peripheral visual fields 
(67).  Grover and colleagues have also compared mfVEP and PVEP in ON confirming 
the superiority of mfVEP in detecting local damage from optic neuritis (68). 
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We could not find studies comparing the utility of the techniques in the setting of 
confirmed chiasmal and retro-chiasmal pathology, particularly using selective half and 
central field in addition to full field stimulation. In this study we assess the relative 
utility of mfVEP compared to PVEP in several cases with pathology at various levels of 
the visual pathway confirmed by other objective techniques. 
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2.2 Aims and methodology   
Subjects 
Six patients with different visual pathway pathology diagnosed by a neurology 
consultant were selected from a large neurology/neuro-ophthalmology service. The 
selected cases included vascular ischaemic events, compressive optic neuropathy and 
inflammatory demyelinating event. The tenets of the Declaration of Helsinki were 
followed and informed consent was obtained from all patients.  
MfVEP recording  
Stimulus display 
MfVEP testing was performed using Accumap (ObjectiVision Pty. Ltd., Sydney, 
Australia). The stimulus consisted of a cortically scaled dartboard pattern of 58 
segments (eccentricity up to 24°). Each segment contained a 4 × 4 grid of black (1.1 
cd/m
2
)-and-white (146 cd/m
2
) checks (Michelson contrast, 99%), which reversed 
patterns according to a binary pseudorandom sequence (Fig 2.1). On average, eight runs 
(each has a 54-second duration) were recorded to reach good SNR.  The visual stimulus 
was generated on a 21-in CRT display. Participants were best refracted for near vision 
and were seated 30 cm away from the screen. All recordings were performed 
monocularly.  
  39 
 
Fig 2.1:  a) Cortically scaled reversed pattern visual stimuli with central fixating target 
that changes randomly. b) Normal mfVEP traces of the right eye 
Electrode placement   
Four gold-cup electrodes (Grass Telefactor, West Warwick, RI) were used for bipolar 
recording, with two electrodes placed 4 cm on either side of the inion, one electrode 2.5 
cm above and one 4.5 cm below the inion in the midline. Another electrode is attached 
to the patient’s right ear lobe as the ground electrode. 
MfVEP recordings  
Signals were recorded along four channels around the inion to maximise signal 
detection. The horizontal channel is between the superior and inferior electrodes, the 
vertical channel is between the left and right electrodes, and the oblique channels are 
between the horizontal and inferior electrodes (Fig 2.2). Visual evoked responses were 
amplified 1 × 10
5
 times and band-pass filtered 1 to 20 Hz.  
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Fig 2.2: An illustration for electrode placement used for mfVEP recordings. The four 
channels used to record signals are shown as CH followed by the channel number  
MfVEP amplitude and latency calculation  
OPERA software (Accumap; ObjectiVision Pty. Ltd., Sydney, Australia) was used to 
correlate the pattern-reversal binary sequence with the electrical signals recorded. The 
largest peak-to-trough amplitude within the interval of 70 to 210 ms was selected for 
each channel. The software automatically chose the wave of maximum amplitude 
among the four channels, to create a combined topographic map which then was 
compared to normal built-in database to create amplitude and latency probability plots 
(50). A visual defect for mfVEPs was defined as a cluster of at least 3 abnormal points 
on the amplitude deviation plot with 2 segments p < 0.02 and at least 1 segment p < 
0.01 or a cluster of 3 or more abnormal segments on inter-eye asymmetry deviation plot 
with p < 0.01 or 2 or more zones with p < 0.005 (117). For latency analysis, the second 
peak of the largest wave for each segment was automatically determined for latency 
measurement by a specially designed algorithm. 
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OCT recording and analysis 
OCT was performed using a Spectralis scanner (Heidelberg Engineering, Heidelberg, 
Germany). A peri-papillary circular scan (12° peripapillary ring, axonal protocol, high 
resolution) was used to obtain measurement of RNFL. The pupils were not dilated. Scan 
quality was considered acceptable if the quality scores were more than 25 decibels and 
the scan was well centred on the optic nerve.        
Visual field recording 
Monocular visual fields were tested using HVF analyser (Carl Zeiss Meditec, Inc., 
Dublin, CA). SITA standard 24-2 protocol was used. 
PVEP recording and analysis  
Full-field, right and left half-field and central field VEPs were tested using a Medelec 
Synergy Version 15.0. Pattern reversal stimulation was performed using a Dell CRT 
monitor with a 20” screen, alternating black and white checkerboard stimulation (32 
min checks) reversed at a rate of 2/s.  A fixation point was located in the centre of the 
screen positioned at the corner of four checks. The contrast between black and white 
checks was greater than 80%. The mean luminance of the stimulus was 50 cd/m
2
 and 
there was no change in mean luminance during the reversal of the pattern. The 
luminance of the screen was uniform and varies less than 10% between the centre and 
periphery of the visual field. Lighting in the laboratory room was homogenous with an 
average of room luminance equal to the average stimulus luminance. Monocular testing 
was performed with the non-tested eye covered by an eye patch. Gold cup disc 
electrodes (10 mm in diameter) were used. In accordance with the international 10/20 
system (24), the active electrode placed on the scalp over the visual cortex at Oz with 
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the reference electrode was placed at Fz and the ground electrode placed on the 
forehead. The distance between the patient and the stimulus was 70 cm. Sweep duration 
was 300 ms post stimulus and the electrode impedance was measured prior to each 
recording and was 5Kohms or less. The amplifier band-pass was 3 to 200 Hz. 
VEPs were recorded in two trials for each eye, averaging at least 128 responses. Cut-
offs for normal values were < 112 ms for P100-peak latencies, ≥ 2 µV for amplitudes, 
the inter-eye right to left half field latency asymmetry was 7 ms and the inter-eye left to 
right half field amplitude ratio was 3:1. These cut-off limits were previously established 
laboratory normal measurements and represent values beyond two standard deviations 
from the mean. 
 Brain MRI testing 
Brain MRI was performed using 3.0 Tesla GE MR750 scanners (GE Healthcare, Little 
Chalfont, UK). 
2.3 Results   
Case 1 (branch retinal artery occlusion) 
An 83-year-old woman presented with a five week history of painless right eye visual 
impairment. There were no other visual or systemic symptoms. She had a past history of 
polymyalgia rheumatica and cataract surgery in her left eye. 
On examination, Snellen visual acuity was 6/12 in the right eye and 6/6 in the left. 
Fundus examination of the right eye showed an ischaemic pale retina inferiorly with a 
cholesterol embolus in the inferior retinal artery (Fig. 2.3). Inferotemporal branch 
retinal artery occlusion was diagnosed. Full-field VEP and central VEP amplitude and 
  43 
latency were normal (Fig.2.4). However, mfVEP of the right eye showed significant 
reduction in amplitude in the upper field (Fig.2.5). This correlated well with the 
reduction of RNFL thickness of the right eye inferiorly (Fig.2.6).    
 
Fig. 2.3: Fundus photography of the right eye showing an embolic inferotemporal 
branch retinal artery occlusion 
 
 
Fig. 2.4: Full-field PVEP of the right and left eyes showing normal amplitude and 
latency. The right eye PVEP has higher amplitude and better-defined waveform 
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Fig. 2.5: MfVEP showing reduction of amplitude in the upper field of the right eye 
 
 
Fig. 2.6: OCT showing an inferior RNFL thickness reduction in the right eye 
 
Comments: case 1 
In this case, full-field PVEPs in the affected eye were normal. Moreover, the waveform 
had higher amplitude and was better defined than in the unaffected eye. This 
contradiction is likely caused by the anatomy of the visual cortex. As discussed 
previously, the polarity of the cortical dipoles from the lower and upper hemi-fields is 
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almost opposite. This results in a cancellation effect of amplitude in the non-affected 
eye. In the affected eye, however, since the response from the upper hemi-field is 
almost extinguished, there is no cancellation and the average full-field signal looks 
larger, although it is mostly generated by the lower hemi-field. The findings suggest a 
greater sensitivity of mfVEP compared to full-field PVEP in the setting of pathology 
selectively affecting one horizontal hemi-field.  
PVEP and mfVEP changes in compressive optic neuropathy 
Case 2 (pituitary adenoma) 
A 75-year-old woman presented with a history of progressive visual loss of her left eye 
during the previous six months. She had a history of pituitary adenoma that had been 
operated on in 1998. Visual acuity in her left eye was hand motion with an afferent 
pupillary defect.  Visual acuity in her right eye was 6/9. MRI scans showed residual and 
possibly recurrent pituitary macro-adenoma affecting the left optic nerve and chiasm 
(Fig. 2.7). Visual field perimetry showed almost total visual field loss in the left eye and 
an upper temporal scotoma in the right eye (Fig. 2.8). 
Full field VEP showed no consistent response from the left eye. The right eye full field 
latency and amplitude were normal. The right half-field amplitude of the right eye was 
small (1.2 µV), whereas the response from the left half-field demonstrated a normal 
amplitude (2.3 µV) (Fig. 2.9). PVEP of both half fields of the right eye showed P100 
latency within normal limits. MfVEP showed a clear right eye temporal hemianopia 
with normal amplitude of the left hemi-field (Fig. 2.10). This example highlights the 
importance of mfVEP in accurate detection of vertical hemi-field pathology. 
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Fig. 2.7: Axial T1-weighted MRI with contrast shows a large mass lesion (white arrow) 
occupying the pituitary fossa and extending into the suprasellar cistern and right 
cavernous sinus consistent with a pituitary tumour 
 
 
 
Fig. 2.8: Humphrey 24-2 visual fields showing total visual field loss in the left eye and 
upper temporal scotoma in the right eye 
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Fig. 2.9: Full-field PVEP of both eyes showing no consistent response in the left eye 
and normal amplitude and latency in the right eye. Half-field PVEP of the right eye 
shows smaller amplitude in the right half with normal latency in both half-fields. 
 
 
Fig. 2.10: MfVEP showing total reduction of amplitude in the left eye and temporal 
hemianopia in the right eye 
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Case 3 (pituitary tumor in a multiple sclerosis patient) 
A 51 year-old woman presented with deterioration of vision in her right eye. She 
described it as an area of obscuration in the temporal field. There was no associated 
pain or change in the colour vision. The patient had a long history of MS. 
On examination her visual acuity was 6/ 18 in the right eye and 6/6 in the left eye. The 
optic disc appeared normal. Full-field PVEP of right eye showed delayed P100. The 
amplitude was smaller than the left eye, but still within normal limits (5.5 µv). Half-
field PVEP waves in the right eye were poorly formed on both sides. Left eye full-field 
and half-field VEPs were within normal limits (Fig 2.11). In view of her MS history 
optic neuritis was considered. MfVEP, however, demonstrated a dramatic loss of 
amplitude in the right eye and significant involvement of the left eye, predominantly on 
the temporal side (Fig 2.12).  
An MRI scan of the brain confirmed extensive demyelination in keeping with her MS 
but in addition, a suprasellar mass extending toward the right optic nerve (Fig 2.13).   
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Fig. 2.11: Full-field PVEP of both eyes showing normal amplitude and latency. Half-
fields PVEP of the right eye showing poorly formed waves with reduction of amplitude 
and latency delay. Both half-fields of the left eye were within normal limits  
 
 
Fig. 2.12: MfVEP showing severe reduction of amplitude in the right eye, with apparent 
left eye involvement 
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Fig 2.13: T1-wheighted axial MRI showing suprasellar mass extending toward the right 
optic nerve consistent with pituitary adenoma 
Comments: cases 2 and 3 
Patients with a pituitary adenoma can present to the neuro-ophthalmology clinic with 
visual symptoms secondary to the tumour. Up to 80% of non-functional pituitary 
adenomas and around 20% of patients with growth hormone or adrenocorticotropic 
hormone-secreting tumours will present with visual disturbance as their primary 
complaint (122). The classic visual field defect is a bitemporal hemianopia due to the 
compression of the crossed nasal fibres in the chiasm. Many other variants of the typical 
visual field defect have been reported in the literature (122). Around 16% of patients 
will present to the neuro-ophthalmologist as in case 2 with one eye blind and a temporal 
visual field loss in the other eye. Conventional VEP abnormalities in this setting are 
well described (123) however in case 2 the full-field VEP was normal in the right eye 
and normal in both eyes in case 3. The extent of the defect was more obvious in the 
mfVEP compared with half-field PVEP, which showed only a mild asymmetry in case 
2. Previous studies that have compared mfVEP with HVF in patients with compressive 
optic neuropathies showed a higher sensitivity of mfVEP (53, 124) but there are no 
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studies comparing VEP techniques.  The findings in these cases support the usefulness 
of the mfVEP in this pathological condition.  
PVEP and mfVEP changes in central visual pathway lesions  
Case 4 (anterior choroidal artery infarction) 
A 42-year-old woman presented with a history of acute onset headache, nausea and 
vomiting. This was associated with visual disturbance as well as facial paraesthesia and 
heaviness in the left arm and leg. The symptoms improved over the next 24 hours 
except for the visual disturbance. Her MRI scan showed features consistent with an 
anterior choroidal artery infarction involving the right hippocampus, medial temporal 
lobe and posterior thalamus (Fig 2.14). Visual field testing revealed left relative 
hemianopia (Fig 2.15).  Full-field VEP for both eyes was within normal limits. Left 
field VEP showed lower amplitude and prolonged latency for both eyes, worse in the 
left eye (Fig 2.16). MfVEP confirmed the presence of left superior homonymous 
quadrantanopia (Fig 2.17). 
 
Fig 2.14: Humphrey 24-2 visual fields showing left congruous relative hemianopia  
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Fig 2.15: Full-field PVEP of both eyes showing normal amplitude and latency and half-
field PVEP shows lower amplitude and prolonged latency of the left field in both eyes, 
worse in the left eye 
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Fig 2.16: Flair and T2-weighted images showing signs of infarction (white arrow) 
involving the right hippocampus, medial temporal lobe and posterior thalamus, 
including a region of the lateral geniculate body 
 
 
            Fig 2.17: MfVEP showing left superior homonymous quadrantanopia 
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Case 5 (sub-acute infarcts due to septic emboli) 
A 73-year-old woman presented with a one-week history of fever after a trip to Europe 
and Hong Kong. She was diagnosed with endocarditis and required mitral valve 
replacement. Her condition was complicated by septic emboli with sub-acute infarcts in 
the right occipital, left cerebellar, right parietal and right frontal lobes (Fig 2.18). 
She was left with a residual field defect, but otherwise her neurological function 
returned to normal. The P100 latency and amplitude of full-field PVEP of both eyes 
were within normal limits. Although the half-field PVEPs of the right eye were within 
normal limits, the amplitude was asymmetrical (right half-field 3.1µV, left half-field 
2µV).  Similar findings were seen in the left eye. The latency was within normal limits 
for both sides (Fig 2.19). While full-field PVEP of the left eye amplitude was relatively 
reduced compared to the right eye, half-field PVEP was inconclusive. MfVEP, on the 
other hand, clearly demonstrated an incongruous left homonymous hemianopia, which 
corresponded to the lesion seen on the MRI (Fig 2.20). 
 
Fig 2.18: a) Fast field echo MRI images and b) Diffusion-weighted images (DWI) 
showing sub-acute infarcts in the right occipital lobe 
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Fig 2.19: Fullfield PVEP of both eyes showing amplitude asymmetry not exceeding the 
cut-off for normal values. Half-field PVEP of both eyes is within normal limits 
 
 
               Fig 2.20: MfVEP showing an incongruous left homonymous hemianopia 
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Comments: cases 4 and 5 
Several studies have reported the ability of conventional VEP to detect field loss due to 
lesions involving the visual pathway and higher visual centres (125-129).  Although 
Bradman and colleagues (125) reported that PVEP quadrantic-field testing has a 
sensitivity and specificity in detecting visual field defects, others disagree. Maitland and 
associates (129) concluded that it was possible to lateralize the brain lesion, but not to 
predict the site of the lesion within the hemisphere and therefore, concluded that PVEP 
analysis is of limited value in assessing patients with homonymous or bitemporal 
hemianopias. 
MfVEP, as demonstrated by case 4 and 5, has the capacity to detect abnormalities in the 
posterior visual pathways that may be missed by conventional pattern reversal studies. 
Klistorner and colleagues have previously reported a good correlation between HVF 
defects and mfVEP in patients with retro-chiasmatic visual pathway lesions (118). 
However, it should be noted that in the setting of lesions in higher visual centres (e.g. 
V2/V3) the mfVEP may be normal as it arises mostly from V1 (119).  
Case 6 (ischaemic optic neuropathy) 
A 50-year-old man presented with a history of painless visual loss in his left eye. On 
examination his visual acuity was 6/6 in both eyes but the left optic disc was swollen. 
An MRI scan of his brain and optic nerves was normal. Lumbar puncture was also 
unremarkable. Full-field and half-field PVEP were normal in both eyes (Fig 2.21). HVF 
testing and mfVEP, however, demonstrated a peripheral visual field defect in his left 
eye, which was accompanied by a corresponding reduction in RNFL thickness (Fig 
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2.22). This could only be revealed on full-field PVEP through annular stimulation after 
macular masking. The patient was treated for an anterior ischaemic optic neuropathy.  
 
 
Fig 2.21: Full-field PVEP of both eyes and half-field PVEP of the left eye were within 
normal limits 
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Fig 2.22: (a) Humphrey 24-2 visual fields showing left eye peripheral visual field 
defect. (b) MfVEP traces and amplitude asymmetry maps of the left eye showing 
peripheral reduction of amplitude. (c) The area of amplitude reduction on mfVEP 
correlates well with RNFL thinning on OCT 
 
(b) 
(c) 
(a) 
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Comments: case 6 
Full-field and half-field PVEP were normal in this patient because the majority of 
PVEP is driven by the central 4° of the visual field, which was intact. Hence, despite his 
extensive peripheral visual field defects, he had a normal full-field PVEP and his central 
visual acuity was unaffected. MfVEP, on the other hand, was able to detect pathology 
affecting peripheral fibres with relatively preserved central vision. 
2.4 Discussion   
There is limited number of studies comparing conventional VEP and mfVEP changes in 
cases of confirmed visual pathway pathology (67, 121). This case series demonstrates 
that mfVEP, as an objective test for visual field, is potentially more sensitive than 
conventional PVEP in detecting focal visual pathway pathology. The findings in our 
cases of a normal PVEP response when the central vision was preserved even if there 
was a significant peripheral visual field defect, as in case 1 and 6, can be explained by 
the fact that a large proportion of the VEP is generated by macular fibres. Since the 
macula is responsible for sharp detailed vision, it has a higher density of cones and 
ganglion cells in comparison to the peripheral retina. At the same time, larger numbers 
of cortical neurons are involved in the processing of visual stimuli from the central 
visual field in comparison to the peripheral visual field.  It has been estimated that 
around 50-60% of the visual cortex is devoted to macular representation (130).  In 
addition, studies have confirmed that the ideal check size to obtain best response differs 
based on receptive fields’ location in the retina. Small check sizes are optimal for fovea 
while larger check sizes are better for peripheral visual fields (131, 132). The check size 
used routinely for PVEP stimulation is selected to obtain an optimal response from 
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central and para-central visual fields (133-136) and, as a consequence, is sub-optimal 
for the peripheral retina. 
MfVEP, on the other hand, uses a dartboard pattern of 58 segments that contains 4x4 
checks cortically scaled to increase in size from the centre to the periphery in order to 
optimise the response from different parts of the visual field (137). It is therefore 
capable of greater resolution of visual pathway function including fibres from the 
peripheral visual field. Moreover, mfVEP techniques allow independent assessment of 
fibres subserving different regions of the visual field, minimising the susceptibility to 
phase cancellation and distortion, which may be evident in PVEP as a result of potential 
summation as in case 1 and 2.  
It is important to note that a normal mfVEP does not always mean a normal visual 
pathway. Considerable caution should be exercised if the visual field defects on 
subjective perimetry have the characteristic higher visual centre field defects i.e. 
quadrinopic field defect respecting horizontal midline.  
In summary, mfVEP may provide a more easily demonstrated topographic 
representation of the visual pathway when compared with conventional VEP. The 
independent assessment of different areas in the visual field improves the detection and 
localisation of lesions and provides an objective topographical map that can be used in 
clinical practice. Although the observational nature of the study limits the application of 
the findings to a larger population of patients, the findings support the need for larger 
studies to evaluate the relative utility of mfVEP in this clinical setting compared to the 
conventional pattern reversal technique.  
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3.0 Overview 
In this chapter, the assessment of ON evolution during the first 12 months using mfVEP 
is explored. The chapter has four main sections. The first section briefly reviews 
literature on ON. The second section discusses objectives and methodologies used to 
evaluate ON changes in the current study. The third section includes study results and 
explores a possible relationship between functional and structural measurements used 
and the last section discusses the importance of those results and places them in context 
with previous research in this field. 
3.1 Background  
Optic neuritis clinical presentation 
Typical ON is characterised by inflammation of the optic nerve associated with loss of 
vision. The visual loss usually progresses over a few days to two weeks. Mild orbital 
pain exacerbated by eye movement is often present, although no pain is reported in 10% 
of patients (138).  
The amount of visual loss and speed of recovery vary among patients but continued 
visual deterioration after the first two to three weeks may point to a different diagnosis. 
Visual field loss is nonspecific with almost all types of visual fields having been 
previously reported (139).  Central field scotoma seems to be more characteristic of ON 
(140). Colour vision and contrast sensitivity are typically reduced and a relative afferent 
pupillary defect is present in the majority of unilateral cases. Anterior ON is present 
when the ON lesion is close to the optic nerve head, resulting in optic disc swelling, 
whereas retro-bulbar ON typically spares the optic disc (138). Retinal examination is 
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usually unremarkable. Atypical manifestations such as no light perception, vitritis, and 
severe retinal haemorrhages and exudates may suggest a different diagnosis. 
Differential diagnosis of ON: 
Extensive discussion of the differential diagnosis of ON is beyond the scope of this 
review. However, many disorders can present with a clinical picture similar to ON. 
Thus, meticulous examination and exclusion of those disorders is crucial. Inflammatory 
conditions (such as systemic lupus erythematosus, sarcoidosis, or Behçet’s disease), 
infectious diseases, vascular lesions or space occupying lesions could present with 
similar manifestations but require different types of management and should be ruled 
out through clinical and para-clinical tests (138).  
Epidemiology 
Typical ON patients are young adults (aged 20–40 years), yet, presentation at younger 
or older ages is possible. Females are more frequently affected than males in a ratio of 
2.5:1. The incidence increases in populations living at high latitudes and decreases in 
areas close to the equator. Whites are affected more than blacks but visual outcome 
tends to be worse in blacks. The reported annual incidence of ON ranges from 1 to 5 per 
100,000 (141, 142).   
ON can present as an isolated condition or as a demyelinating attack in patients known 
to have MS.  
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Pathophysiology 
Many aspects of ON pathogenesis are similar to the pathogeneses of MS discussed in 
chapter one. 
Recovery process 
The process of damage and recovery in ON are not totally understood and the time 
course of demyelination and remyelination in lesions is also still indeterminate. 
However, we know that clinical improvement starts early during the recovery process. 
This could be explained by several mechanisms including remyelination, increased 
expression of sodium channels along the demyelinated segment to improve conduction, 
and cortical plasticity (143).  
Myelin regeneration is mainly mediated by oligodendrocyte precursor cells. These cells 
are frequently observed in demyelinating lesions during the early, active stages of ON 
episodes (144). The first signs of remyelination can be observed few days after the 
acute onset of demyelination (145).  Although the precise role of inflammation in 
promoting remyelination is still unclear, it is believed that the acute inflammation 
provides the required environment for many of the regulators needed for remyelination, 
which are absent in more chronic settings. For example, macrophages, which initially 
appear at the border of demyelinated lesions, play an important role in the phagocytosis 
of myelin-associated inhibitors aiding remyelination in the early stages (146). 
Furthermore, the recovery of function requires secure action potential conduction. 
Several studies have demonstrated an increase in the expression of sodium channels as a 
mechanism to restore impulse conduction after a demyelinating attack (147). 
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The third mechanism that could contribute to rapid recovery after acute ON is cortical 
adaptation. Functional MRI (fMRI) studies of optic neuritis patients have shown that 
there is an increased activation in higher visual centres in response to binocular 
stimulation but that these changes have subsided after a few months, suggesting that 
temporary adaptive changes happen during recovery (143, 148).  Rocca and colleagues 
evaluated the extent to which the fMRI changes correlated with the total axonal injury 
in clinically isolated syndromes, including ON, brain stem injury, and spinal cord 
syndromes. They showed that acute axonal injury could elicit adaptive cortical 
reorganisation in order to limit the functional effects of irreversible axonal damage 
(149).   
ON prognosis and MS risk 
Recovery from ON is generally good but many patients are at a greater risk of 
recurrence and/or progression to MS. A great amount of our knowledge on the natural 
history of ON is drawn from the Optic Neuritis Treatment Trial (ONTT), where 457 
acute ON patients were enrolled in to a randomised control study (150).  These patients 
were followed up for visual outcome, recurrence rate and risk of MS development after 
15 years’ time (151).  
Pain associated with ON generally lasts for only a few days. After around two weeks, 
spontaneous improvement of vision takes place. Initial improvement is rapid which is 
followed by slower recovery of vision for up to a year after the initial episode.  Ninety 
percent of patients in the ONTT had a visual acuity better than 6/12 by the end of first 
year (151). However, the amount of visual loss at presentation seems to influence the 
final visual outcome. The proportion of patients with 6/12 vision decreased to 64% in 
patients with visual acuity of light perception on presentation (138).  
  66 
Persistent residual deficits are frequent including reduced contrast sensitivity and colour 
saturation deficits. Patients also may complain of vision fluctuation with increased body 
temperature, known as Uhthoff’s phenomenon (152).  
The risk of having recurrent ON after five years of follow-up in either eye was 28% in 
the ONTT. Recurrence was more frequent in MS patients and in patients who received 
oral prednisolone (153). The risk of MS after ON becomes greater as the length of the 
follow-up period increases. In a cohort study of 156 ON patients, the 10-year risk of 
multiple sclerosis was 39% but increased to 60% by 40 years (141). The most important 
risk factor for the development of MS is the presence of white-matter lesions on MRI of 
the brain. In the ONTT, the 5-year risk of MS was 16% in patients with no MRI lesions 
in comparison to 51% in patients with more than two brain lesions (154). Another study 
evaluated the risk of MS in patients with different clinically isolated syndromes 
including ON, spinal cord and brainstem sundroms and showed that the 10-year risk for 
MS in patients with normal MRI was 11% while the risk increased to 83% in patients 
with one or more lesions consistent with demyelination (155). Other risk factors that 
have been related to developing MS are being female, HLA-DR-positive and having 
oligoclonal bands in the CSF (156, 157).  
Assessment of ON damage  
Damage from ON can be evaluated by several available tests. Different tests are aimed 
to capture different aspects of function and structure changes. Subjective visual acuity 
using Snellen chart or logMAR scoring is commonly used in clinical practice and 
research. Low contrast acuity charts were found to be more sensitive in detecting visual 
dysfunction in mild ON cases and after visual acuity recovery (158). Colour testing can 
be done with Ishihara plates, which are more readily available in the clinical setting or 
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with the Farnsworth-Munsell 100-hue test, which is more comprehensive and preferred 
in research practice (159). The visual field can be tested with several tools but most 
commonly either with a static target using Humphrey perimetry or with a kinetic target 
using Goldmann perimetry. The choice of which to select is usually a balance between 
the advantages and disadvantages of those tests.  
Imaging the optic nerves can be challenging because of several factors such as their 
small size, movement artifacts, and the fact that they are surrounded by fat, CSF, and air 
sinuses makes it difficult to identify them accurately. However, rapid advances in 
imaging techniques have improved the quality of images and allowed quantitative data 
to be collected. It has been reported that an abnormal contrast enhancement of the optic 
nerve is evident in more than 90% of acute ON cases. However, the location and length 
of the enhanced segment was not correlated to visual recovery (160). 
 Lesions to the optic nerve cause physical and/or functional transection of axons and 
subsequent retrograde degeneration resulting in changes in RNFL thickness. Early 
evidence supporting such hypotheses came from animal studies with ON models where 
optic nerve transection and retrograde RGC degeneration were evident after such events 
(161, 162).  
Peripapillary RNFL thickness is of particular interest in optic neuropathies. RNFL 
thickness can be measured reliably using OCT to quantify axonal loss through creating 
a high resolution cross sectional image of the retinal layers by measuring the 
backscattered infrared light generated from low-coherence interferometry. Parisi and 
colleagues were the first to report a reduction in RNFL thickness following ON using 
OCT (163). Numerous studies have confirmed this finding compared to fellow 
unaffected eyes and to controls (63, 164-167).  
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Functional assessment of ON damage using PVEP and mfVEP has been discussed in 
chapter one. Several studies have demonstrated a correlation between VEP parameters 
and other functional and structural visual tests including visual acuity, MS disability 
scales, RNFL thickness, and optic nerve atrophy (41, 168-170). Having an agreement 
between functional and structural tests in general is useful clinically as it helps to 
overcome some of the limitations of each individual test and captures various stages of 
injury and repair. A good correlation between amplitude and RNFL thickness measured 
by OCT was reported previously in ON after the resolution of optic disc swelling (63, 
75, 77). In a cross-sectional study of 32 patients with ON, Klistorner and colleagues 
demonstrated a good correlation between mfVEP parameters and RNFL thickness (63). 
MfVEP amplitude had a better correlation (r = 0.9) with RNFL thickness compared to 
the latency (r = ‒0.6). Similar findings were reported in another cross-sectional study 
which demonstrated a topographic association between the amplitude and reduction of 
RNFL thickness in ON eyes (75). Furthermore, mfVEP changes have been observed in 
the fellow eyes after ON, although these changes are usually subtle and asymptomatic 
(63, 171).  
 Previous cross-sectional studies have noted a difference in mfVEP parameters in ON 
eyes when patients were stratified on the bases of their risk for developing MS, where 
MS-related ON eyes showed sectorial latency delay on the mfVEP map (76, 172). 
Another cross-sectional study reported mfVEP changes in fellow eyes in MS-related 
ON, suggesting a possible insidious inflammatory demyelination process (171).  
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3.2 Aims and methodology   
Purpose of the study  
1. To evaluate mfVEP evolution in both affected and fellow eyes during the first 
12 months after a unilateral acute ON 
2. To investigate whether mfVEP measurements differ based on participants’ MRI 
findings and their future conversion to MS 
3. To study the relationship between functional and structural changes by 
measuring RNFL thickness at the twelfth month and correlating it with mfVEP 
amplitude changes during different follow-up time points 
Rationale of the study  
Most of the studies that have addressed the mfVEP changes after ON were cross 
sectional, had relatively small sample sizes or did not take MRI findings into 
consideration (76, 78, 79, 171, 172). Therefore, there is a need for a longitudinal 
analysis examining a larger sample size of patients with ON and assessing changes in 
both affected and fellow eyes simultaneously to provide a better understanding of 
mfVEP changes and the time frame of their occurrence. Finding a significant mfVEP 
difference between different patient groups may shed a light on subtle pathological 
changes and suggest a potential role for mfVEP in identifying early pathological 
dysfunction.  
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Methodology  
Subjects 
Patients with clinically diagnosed typical acute unilateral ON were recruited from 
Sydney Eye Hospital and The Royal Victorian Eye and Ear Hospital. 
The inclusion criteria were:    
 Adult (>16 years old) presenting with ON with no previous history of other 
inflammatory demyelinating attacks  
 Signs and symptoms of typical acute ON including visual acuity and colour 
vision reduction, afferent pupillary defect and pain on eye movement (138) 
The exclusion criteria were: 
 History of previous demyelinating events 
 Atypical presentation (138) 
 Involvement of the other eye 
 Presence of other ophthalmic conditions that could affect the mfVEP or OCT 
measurements (for example, optic neuropathies such as glaucoma, dense 
cataract, retinal detachment or amblyopia) 
 Mental or physical disabilities, which require continuous and special care, as 
this may interfere with performing reliable tests  
 Inability to fixate at a point from 30 cm distance due to poor vision (usually if 
best corrected vision is less than 6/60) 
Potential participants undertook a full ophthalmic examination and patients matching 
the inclusion criteria were offered to be part of the study. Twenty-five age-and-gender 
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matched healthy subjects were recruited from the general community as controls. All 
procedures adhered to the tenets of the Declaration of Helsinki. Test procedures and 
other related concerns were discussed and informed consent was obtained from all 
participants. Ethical approval was obtained from the Human Research Ethics 
Committee of the University of Sydney (protocol no. 2013/106).  
Patients had an MRI within two weeks of the ON attack and at least one follow-up MRI 
within the next 12 months. MfVEP recordings were performed at 1, 3, 6 and 12 months 
from the onset of ON. OCT was performed at 12 months post-attack.  
Controls underwent visual acuity testing, ophthalmic evaluation, and were tested once 
using mfVEP and OCT.  
As a standard of care, all ON patients were followed up in the neurology/neuro-
ophthalmology clinic with routine clinical and MRI assessment. Within the following 
four years, participants were retrospectively stratified to three groups: 
 Group 1: multiple sclerosis (MS) – ON patients who converted to MS 
(diagnosis was made based on revised McDonald Criteria for multiple sclerosis) 
(173) 
 Group 2: high risk group (HR) – ON patients with MRI lesions who did not 
fulfil the McDonald Criteria for MS  
 Group 3: low risk group (LR) – ON patients with normal MRI 
 Group 4: (control) – age-and-gender-matched controls 
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Study procedures 
MfVEP recording and analysis 
MfVEP was recorded as described in methodology section of chapter two. In order to 
accurately follow the evolution of the latency after the ON attack, only eyes that had at 
least 44/58 (75%) of traces with sufficient amplitude at one month post-attack were 
included. To determine sufficient amplitudes, the software automatically calculated the 
SNR at each segment of the stimulated visual field. The signal was considered non-
recordable in segments where the amplitude of the response was less than 1.96 times 
that of the noise level (determined as standard deviation of the trace within the interval 
400-1000 ms) (80). The amplitude of multiple segments added after cross-correlation is 
performed and individual traces are defined, avoiding, therefore, cancellation of the 
dipoles, which often occurs in full-field VEP. Mean values of both amplitude and 
latency, which were used in the final analysis, were calculated by averaging the 
amplitude and latency of the individual sectors (see mfVEP example in Fig 3.1).  
 
Fig 3.1: MfVEP of a patient with left eye optic neuritis showing localised amplitude 
reduction centrally with latency delay 
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OCT recording and analysis 
OCT was performed by a trained operator using Stratus OCT-3 scanner (Stratus; Carl 
Zeiss MeditecInc, Dublin, California, USA). When the study began the Stratus OCT 
machine was the standard machine in the clinics. The Fast RNFL protocol, consisting of 
three circular scans with diameters of 3.4 mm centred on the optic disc was used. The 
pupils were not dilated. The OCT scan was considered acceptable if the signal strength 
score was 7 or more and the scan was well centred on the optic nerve. The mean total 
RNFL thickness was assessed.  
Inter-eye asymmetry analysis 
Inter-eye asymmetry has been used earlier in studies of both mfVEP and RNFL 
thickness and has proved to be more sensitive in detection of abnormality as well as 
revealing relationships between various measures compared to absolute values (48, 164, 
168). Therefore, the inter-eye asymmetry of both amplitude and latency of the mfVEP 
and inter-eye asymmetry of RNFL thickness were calculated and analysed in this study. 
The inter-eye asymmetry was calculated as a difference between fellow and affected 
eyes and was expressed in nanovolts, milliseconds and micrometers for mFVEP 
amplitude, latency and RNFL thickness respectively. 
In addition, the correlation between mfVEP amplitude asymmetry at different time 
points of follow-up and RNFL thickness at 12 months was evaluated. The 12-month 
cutoff point was selected because RNFL thickness is known to be affected by oedema 
during the acute period of inflammation and it takes time for retrograde degeneration to 
reach the retina after the transection of optic nerve fibres during the acute attack. 
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Latency Z-scores were calculated for each patient using following formula: 
(Patient’s latency ‒ mean normal latency) / Normal latency standard deviation.  
A Z-score greater than 1.96 was classified as latency delay. 
Statistical analysis 
Statistical analysis was performed using SPSS 21.0 software. To evaluate the pattern of 
amplitude and latency change over time, we tested the trend of change with mixed 
model repeated measure analysis using the follow-up visits as a continuous variable.  
One-way ANOVA was used to assess difference between groups. As the examined 
variables followed a normal distribution, a Spearman rank correlation and linear 
regression analysis were used to determine correlations between the mfVEP values and 
OCT values. A p value of 0.05 or less was considered statistically significant. 
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3.3 Results  
A total of 98 patients with typical acute ON were enrolled. Subsequently, 11 ON 
patients were excluded from analysis: three participants due to a second episode of ON 
in the same eye during the 12-month study period, six due to an ON attack in the other 
eye during the study period; one patient due to noisy traces; and another one due to the 
development of a maculopathy that interfered with reliable measurements. Therefore, 
the total number of enrolled participants was 87 patients and 25 controls. 
Demographic and clinical characteristics of participants 
At presentation, 27 of the 87 patients without other demyelinating MRI lesions were 
classified as low risk (LR) for developing MS. Sixty of the 87 patients had brain and/or 
spinal cord demyelinating lesions on MRI, but did not meet the criteria for a diagnosis 
of MS. This group was considered to be at high-risk (HR) for developing MS (174). 
During the follow-up period (range 1-4 years) after the attack, 38 patients converted to 
MS with 36 from the HR group 60 (60%) and 2 from the LR group of 27 (7%).  
 The demographic and clinical characteristics of the study participants are summarised 
in Table 3.1. There was no significant difference between groups with respect to age (p 
= 0.6, one-way ANOVA). The LR group displayed a higher male: female ratio 
compared to patients who converted to MS and the HR group. 
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Table 3.1: Demographic and clinical characteristics of the study participants 
 Controls Patients 
converted to 
MS 
Patients 
remained at 
HR 
Patients 
remained at LR   
Number of 
subjects 
25 38 24 25 
Mean age 35.9±11.2 34.4±10.5 33.9±8.3 36.5±11.3 
Male: female 
ratio 
6:19 9:29 6:18 9:16 
    Abbreviations: MS, multiple sclerosis; HR, high risk; LR low risk. 
 
Amplitude of mfVEP in ON eyes 
Entire study cohort 
There was a significant reduction of amplitude at one month in ON eyes compared to 
normal controls and fellow eyes (p < 0.0001, one-way ANOVA; p < 0.0001, post hoc 
Tukey test). During the 12-month follow-up period, amplitude recovered significantly 
(p < 0.01, mixed model repeated measure analysis). The largest improvement in 
amplitude was seen within the first three months (Fig 3.2a). Although the amplitude 
continued to improve after three months, the change was not significant (p = 0.47, 
mixed model analysis repeated measure analysis).  
At the 12-month time-point, amplitude remained significantly reduced compared to 
both controls and fellow eyes (p < 0.0001, one-way ANOVA; p < 0.0001, post hoc 
Tukey test). 
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Group analysis 
Separate analysis of LR, HR and MS patients revealed a similar trend for all three 
groups with a significant difference between the ON eyes versus fellow eyes and 
controls (p < 0.01) (Fig 3.2a). 
 
Fig 3.2: (a) Amplitude changes during the study period in the ON eyes in patient 
groups. (b) Latency recovery during study period in ON eyes. Bars show standard error 
of the mean (entire study cohort is shown as a cross, LR as triangles, HR as squares, and 
MS as diamonds) 
The mean amplitude of the MS group was less than in the HR and LR groups 
throughout the study period, but this difference did not reach statistical significance at 
any point in time.  
The largest improvement in amplitude, in all three groups, was seen within the first 
three months (p = 0.03, 0.05, 0.02, for MS, HR, and LR respectively) with modest, but 
not significant, improvement afterward (p= 0.5, 0.3, 0.6 mixed model repeated measure 
analysis for MS, HR, and LR respectively). 
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Latency of mfVEP in ON eyes 
Entire study cohort 
As discussed in the methods section of this chapter, only eyes that had at least 75% of 
traces with sufficient amplitude at one month for latency to be reliably measured were 
included, leaving 57 eyes (MS – 24; HR – 18; LR – 15) suitable for analysis. 
ON eyes had a substantial mfVEP latency delay at one month when compared to 
controls and fellow eyes (p < 0.0001, one-way ANOVA; p < 0.0001, post hoc Tukey 
test). A significant trend of latency recovery was observed during the entire follow-up 
period (p < 0.001, mixed model repeated measure analysis) (Fig 3.2b). The average rate 
of latency recovery was 1.33 ms/month between one and three months, which declined 
between three and six months to 0.76 ms/month, and slowed to 0.33 ms/month between 
six and twelve months. 
There was still a significant residual latency delay at 12 months in comparison to 
controls and fellow eyes (157.9 ±8.3, 145.6±6.7, 141±5.1 ms, for ON, fellow eyes and 
controls respectively; p < 0.0001, one way-ANOVA-post hoc test).      
Group analysis 
Affected eyes in all groups showed significant latency delay in comparison to controls 
and fellow eyes throughout the study period (p ≤ 0.003). 
All three groups followed a similar trend of latency recovery (p < 0.001, mixed model 
repeated measure analysis for each group) (Fig 3.2b).  
The LR group had less latency delay throughout the study period. There was a 
significant difference in latency delay between the LR group and the MS and HR 
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groups at three months (p = 0.01, one-way ANOVA; p =0.01 for MS and p=0.05 for 
HR, Tukey post-hoc analysis) and six months (p = 0.01, one-way ANOVA; p=0.01 for 
MS and p=0.05 for HR, Tukey post-hoc analysis). The latency difference between 
groups decreased at 12 months (p = 0.057, one-way ANOVA). 
Analysis of the latency Z-scores also revealed that a smaller proportion of ON eyes in 
the LR group were abnormal as compared to the MS and HR groups (Table 3.2). 
 
Table 3.2: Z-scores*of latency for ON eyes and fellow eyes according to patients 
subgroups 
 ON eye Fellow eye  
Subgroup Z-score ≥ 2 
at 1month  
Z-score > 2 
at 12 months 
Z-score > 2 
at 12 months 
MS 21/24 (88%) 17/24  
(71%) 
9/24 
(38%) 
HR 17/18 (94%) 13/18  
(72%) 
4/18 
(22%) 
LR 9/15 (62%) 5/15  
(36%) 
0/15  
(0%) 
Total  47/57 (82%) 35/57  
(61%) 
13/57  
(23%) 
*Z-score less than 1.96 classified as normal latency 
Abbreviations: ON, optic neuritis; MS, multiple sclerosis; HR, high risk; LR low risk 
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Retinal nerve fibre thickness analysis  
At the 12-month test, the RNFL thickness of the entire cohort was significantly reduced 
in ON eyes in comparison to fellow eyes (84 ± 16 vs. 10 3± 11 µm, p = 0.0001). This 
reduction was similar between the three studied groups (p = 0.46, one-way ANOVA). 
To assess the predictive power of mfVEP amplitude on long-term axonal loss, the 
mfVEP amplitude at every time point was compared with final inter-eye asymmetry of 
the RNFL thickness. A high degree of correlation between the mfVEP amplitude and 
RNFL thickness was seen as early as three months after the attack, and this increased 
marginally with time (Table 3.3). Separate analysis for each group was also performed. 
A Similar trend was observed for all groups. The correlation by three months was 
already strong, but continued to improve with time (Table 3.3).  
 
Table 3.3: Linear correlation between relative asymmetry of mfVEP amplitude and 
retinal nerve fibre thickness. 
 R² of relative asymmetry of amplitude over time vs. 12month RNFL 
thickness asymmetry 
Patients 
Group 
1month 3months 6months 12months 
Total 0.28 p<0.001  0.59 p<0.001 0.61 p<0.001 0.71 p<0.001 
MS 0.27 p=0.0008 0.63 p<0.001 0.6 p<0.001 0.73 p<0.001 
HR 0.29 p=0.006 0.59 p<0.001 0.71 p<0.001 0.75 p<0.001 
LR 0.29 p=0.005 0.49 p<0.001 0.65 p<0.001 0.68 p<0.001 
Abbreviations: RNFL, retinal nerve fibre layer; MS, multiple sclerosis; HR, high risk; 
LR low risk 
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Amplitude of mfVEP in fellow eyes 
Entire study cohort 
The fellow eyes demonstrated lower amplitude in comparison to controls (p < 0.001, 
one-way ANOVA) at all time points. There was no significant change in the amplitude 
throughout the study period (p = 0.5, mixed model repeated measure analysis) (Fig 
3.3a).           
Group analysis 
The amplitude in the fellow eye was significantly lower in all three groups, however the 
LR group demonstrated less amplitude reduction compared to the HR and MS groups (p 
< 0.01 for all).  
The amplitude of the fellow eye in the LR group remained stable during the follow-up 
period (Fig 3.3a), while progressive amplitude reduction in the fellow eye was seen in 
the MS group with the difference between the MS and LR groups reaching significance 
at six months (p = 0.01, one-way ANOVA; p = 0.02, post-hoc) and at 12 months (p = 
0.02, one-way ANOVA; p = 0.03, post-hoc).  
Latency of mfVEP in fellow eyes 
Entire study cohort 
Latency of the fellow eye was not significantly delayed at the first visit in comparison 
to the controls (p = 0.17). However, a slow but consistent increase in latency was seen 
during the study period. By three months this latency delay reached significance (p = 
0.03), which continued to increase during subsequent visits (p = 0.02, and 0.018 in the 
six and 12-month visits) (Fig 3.3b).  
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Fig 3.3: (a) Amplitude changes during study period in fellow eyes. (b) Latency changes 
during study period in fellow eyes. Bars show standard error of the mean (entire study 
cohort is shown as a cross, LR as triangles, HR as squares, and MS as diamonds) 
 
Group analysis 
There was no significant difference between the latency of each individual group and 
normal controls at one month (p = 0.2, one-way ANOVA). By three months, the MS 
group displayed significant latency delay compared to controls (p = 0.024, one-way 
ANOVA; p = 0.023, Tukey test post-hoc). This trend continued at six and 12-months 
visits (p = 0.018, one-way ANOVA; p = 0.013, Tukey test post-hoc, and p = 0.01, one-
way ANOVA; p = 0.01, Tukey test post-hoc respectively) (Fig. 3.3b). 
While latency delay of the fellow eye in HR group increased over time, it was not 
statistically significant. The latency of the LR group remained stable. 
Z-score analysis of the fellow eyes revealed abnormal latency in more than third of 
patients (38%) who converted to MS, but none of the patients from the LR group (Table 
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3.2). The HR group occupied an intermediate position with 22% of fellow eyes 
displaying abnormally long latency. 
Asymmetry analysis. 
As noted above, the amplitude of ON and fellow eyes in the MS group was generally 
lower compared to the other two groups. To examine the possible effect of posterior 
visual pathway damage on these results, an inter-eye asymmetry analysis of the 
amplitude was performed. It demonstrated no significant difference between groups at 
any time point (p = 0.6, 0.3, 0.3, 0.4 for one, three, six and 12 months respectively, one-
way ANOVA) (Fig 3.4a), suggesting that the difference in amplitude between the 
groups is likely due to retro-chiasmal damage.  
In addition, all three groups demonstrated very similar trends in latency recovery. There 
was less latency asymmetry in the LR group compared to the MS and HR groups, 
which, however, did not reach statistical significance at any time points (p = 0.2. 0.07, 
0.18, 0.29 for one, three, six, 12 months respectively, one way-ANOVA) (Fig.3.4b). 
 
Fig 3.4: (a) Amplitude inter-eye asymmetry changes during study period. (b) Latency 
delay inter-eye asymmetry during study period in patient groups. Bars show standard 
error of the mean (MS group is shown as diamonds, HR as squares, and LR as triangles) 
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3.4 Discussion 
This report provides prospectively acquired, longitudinal mfVEP data over 12 months 
of patients presenting with ON as clinically isolated syndrome.  During the following 
four years 58% of patients who had lesions on initial MRI scans converted to MS, while 
only 7% of patients without initial MRI lesions developed the disease. While the 
conversion rate is lower compared to other reports (155, 175), the follow-up period in 
this study is considerably shorter. Therefore, more patients, particularly from the HR 
group, are expected to develop MS. The study demonstrated that both the amplitude and 
latency of the mfVEP are grossly abnormal at the early stages of ON. While amplitude 
of the mfVEP improves considerably during the first year after acute ON, the majority 
of the recovery occurred within the first three months. These results are similar to those 
reported for full-field VEPs (176). This pattern of amplitude recovery is also in line 
with visual acuity, which demonstrates rapid improvement of vision within the early 
post-acute period (33, 79). 
Similar to amplitude, the speed of latency recovery was fastest during the first three 
months.  It is believed that latency shortening after ON is mostly due to the process of 
remyelination. Remyelination occurs most efficiently during the early post-acute stage, 
where cells engaging in the formation of new myelin sheaths are frequently observed 
(144). The environment for successful remyelination may be severely altered afterward 
(177). Thus, the significant latency recovery during the first few months after the attack 
supports the concept of a “window of opportunity” as being fundamentally important 
for the success of remyelination (177, 178). 
Spontaneous remyelination, which is an early and frequent phenomenon in MS, is often 
incomplete (144, 179). Our results confirm this, as we showed significant residual 
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latency delay even 12 months after acute ON. This chronically persisting latency delay 
has been demonstrated in multiple studies and remains the major hallmark of previous 
ON (180). 
In this study, patients were divided into groups of those who converted to MS and those 
who remained at high risk or low risk of conversion to the disease. Overall, the group 
analysis demonstrated smaller amplitude and longer latency in the ON eyes of MS 
patients compared to LR patients. However, the progressive deterioration of both 
amplitude and latency in the fellow eyes of the MS group, and to a lesser extent the HR 
group, suggests that the apparent more severe involvement of ON eyes in these 
subgroups is due to superimposed burden of subclinical inflammatory demyelinating 
activity along the posterior visual pathway. Hence, the severe involvement of ON in the 
MS group is likely to be an indirect reflection of lesion load and disease burden at 
presentation and not related to the difference in remyelination pattern between the MS 
and LR groups.  
The latency of the fellow eye in the LR group did not differ from the latency of normal 
controls and was stable throughout the study period. However, there was a clearly 
visible trend of latency increase in the fellow eye of the MS group. The difference 
between MS patients and controls reached statistical significance by three months and 
continued to increase thereafter. The latency of the fellow eye in the HR group also 
demonstrated a tendency to increase, although not to the same extent as patients in the 
MS group. Delayed latency in the fellow eyes of ON patients has been suggested as 
being part of central adaptive mechanism at the cortical level to compensate for delayed 
cortical visual input from ON eyes (181). The fact that the fellow eyes of the LR 
subgroup in this study did not show significant latency delay argues against this 
suggestion. Since both ON and fellow eyes appear to be involved, it is reasonable to 
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assume that this pathological process is occurring in a post-chiasmal location. The optic 
tract and OR are two potential sites of such retro-chiasmal lesions. Lesions of the optic 
tract, however, are rare in MS (43, 182). Furthermore, it is unlikely for the acute 
inflammation of the optic tract to be missed clinically due to its small diameter and 
supposedly preferential damage of small central fibres (183), which would result in an 
acute binocular visual deficit.  
On the other hand, OR lesions are very common in MS (184) and are often clinically 
silent. This apparent clinical “invisibility” is due to a wide spread of OR fibres, and 
non-preferential distribution of the lesions, which causes rather small and more 
peripherally located visual field defects, easily missed by patients. However, since 
mfVEP covers a significant part of the visual field (48°), demyelinating lesions of the 
OR are likely to cause amplitude reduction and latency delay for both ON and fellow 
eyes. Consistent with this, as will be discussed in chapter five, we reported a correlation 
between the volume of OR lesions and latency delay in the fellow eyes of MS patients 
(185). The findings of this study also concur with previous reports demonstrating that 
latency prolongation and amplitude decline 12 months after acute ON were proportional 
to the risk of MS (171). Likewise, full-field VEP studies have also suggested that the 
cause of the observed asymptomatic deterioration of VEP latency in unaffected eyes of 
MS patients is a demyelinating process in the posterior visual pathway (176).    
Therefore, to analyse the effects of acute ON on the amplitude and latency of the 
mfVEP, the potential effect of retro-chiasmal damage has to be eliminated. Assuming 
that retro-chiasmal damage influences both eyes similarly, its effect can be removed by 
subtracting values of the fellow eye from the ON eye. Consequently, inter-eye 
asymmetry analysis showed no difference in amplitude reduction, recovery or residual 
deficit between patients who converted to MS and patients who remained at high risk or 
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low risk of conversion to MS, indicating a similar degree of inflammation caused by 
acute ON for all three groups. This is also supported by high (and very similar) 
correlation between the residual amplitude of the mfVEP and RNFL thickness in all 
three groups and by the similar inter-eye asymmetry of the RNFL thickness between the 
groups. 
Results of the inter-eye latency analysis also revealed a similar picture, suggesting that 
the demyelinating effect of the acute ON is independent of MS. 
While several studies have reported a shorter latency in eyes with acute ON as part of 
mono-symptomatic disease (analogous to the LR group) as compared to MS-related ON 
(186-188), none of them assessed the potential effect of retro-chiasmal pathology by 
analysing inter-eye asymmetry. Our data, however, indicates that retro-chiasmal 
demyelination is the major factor contributing to differences in amplitude and latency 
between MS and non-MS patients. 
Another important aspect of this study is a demonstration of an early predictive power 
of mfVEP amplitude in post-ON axonal loss. The amplitude reduction predicted a 
significant portion of the final axonal loss as early as three months. The early 
association of mfVEP amplitude with the degree of post-inflammatory neuronal loss 
may suggest a possible role of the electrophysiological measure as a potential functional 
surrogate marker in neuro-protective trials.  
The limitation of this study is its retrospective design in regards to conversion to MS. 
Therefore, a significant number of patients in the HR group and some patients in the LR 
group are in reality MS patients, who, due to limited follow-up time, have not yet 
demonstrated evidence of conversion to MS. Another limitation is the use of time-
domain OCT. Since there is a low incidence of ON in Australia, the enrolment process 
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took several years and started at the time when spectral-domain OCT machines were 
not yet available. However, we believe that for the purpose of the current study the 
resolution of time-domain OCT was adequate. 
In conclusion, in this longitudinal analysis of mfVEP evolution of ON we demonstrated 
significant recovery of the amplitude and shortening of the latency during the 12-month 
follow-up period, which was fastest within the first three months after an acute episode. 
We also showed a high predictive value of mfVEP amplitude in subsequent axonal loss 
as early as three months after acute ON. Our result suggested the presence of the 
progressive retro-chiasmal inflammatory demyelination in patients with MS-related 
disease. 
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Chapter four: Mechanism of delayed conduction of fellow 
eyes in patients with clinically isolated optic neuritis 
 
(The results of this chapter have been submitted to clinical electrophysiology) 
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4.0 Overview 
The delayed conduction of fellow eyes in patients with clinically isolated ON and MS-
related ON is analysed in more depth in this chapter by evaluating latency and 
waveform of mfVEP traces from individual segments. Four sections are included in this 
chapter. The first section briefly reviews the VEP changes in fellow eyes after ON. The 
second section discusses the aims and methodology used in the current study. Results 
are described in section three and the findings are discussed and placed in the relevant 
context in the last section of this chapter. 
4.1 Background  
ON can be a single demyelinating episode of unknown aetiology or a manifestation of 
MS. Patients with ON, presenting as clinically isolated syndrome, have a 40% risk for 
developing MS within 10 years’ time (138, 141). Chapters one and three included a 
detailed discussion on VEP amplitude and latency changes in ON eyes. In brief, the 
amplitude of the VEP reflects the number of functional afferent fibres reaching the 
striate cortex, which is determined by a combination of the severity of the inflammation 
(acute or chronic) along the visual pathway, axonal degeneration and the degree of 
synaptic activity in V1 (176). Therefore, diminished amplitude indicates either 
inflammatory conduction block or axonal atrophy, or both. 
Delayed conduction of the VEP in the affected eye has been found in the majority of 
patients with ON and is thought to reflect demyelination of the optic nerve fibres (21, 
189) while a subsequent shortening of latency is thought to represent the process of 
remyelination (59, 176). Significant latency delay is also found in a large proportion of 
MS patients with no history of ON (37, 180, 190, 191). 
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An alteration of the VEP has been reported in the fellow eyes of patients with ON in an 
absence of clinical symptoms (32, 171, 192-194). In a small group of ON patients (n = 
12), Brusa and colleagues reported a significant subclinical VEP latency deterioration in 
the fellow eyes during the first three years after an ON attack (32). Beck and colleagues 
found that ON patients with fellow eye abnormalities are more likely to have clinical or 
MRI evidence of MS than ON patients with normal fellow eyes (193). Similar findings 
were reported in a cross-sectional study using mfVEP (171) and were in agreement with 
our longitudinal study included in the previous chapter of this thesis, which reported a 
significant deterioration of amplitude and latency of fellow eyes in patients with MS-
related ON. The reported VEP changes in the fellow eyes have been attributed to 
various factors including sub-clinical ON, inflammation spillover from the affected eye 
at the chiasm or retro-chiasmal inflammatory demyelination, which is frequent in ON 
patients with MS (171, 192-194).  
Recently, however, adaptive cortical plasticity has been suggested as an important 
factor that may contribute to prolongation of the latency in the fellow eye. It has been 
argued that temporal reorganisation at the cortical level causes latency delay in fellow 
eyes to compensate for delayed transmission of visual information, which serves to 
improve binocular vision (181). 
In the current study, we tested this hypothesis by analysing the latency and waveform 
changes of mfVEP traces in fellow eyes of ON patients during the first 12 months after 
acute ON. MfVEP provides a unique opportunity to evaluate locally induced responses, 
therefore increasing the technique’s sensitivity and improving its spatial resolution by 
minimising waveform cancellation effect and including peripheral visual field segments 
(47). 
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4.2 Aims and methodology   
 Aims of the study  
1. To assess the latency delay in fellow eyes of ON patients by evaluating mfVEP 
traces at early (three months) and late (12 months) periods after ON through 
measurements of the first and second peaks of mfVEP traces and assessment of 
their waveform changes in comparison to age-and-gender matched controls 
2. To evaluate the correlation between the latency delay of ON eyes and latency 
change of both peaks of fellow eyes. The assumption is that patients with more 
latency delay in the affected eyes would experience more delay in the fellow 
eyes if the original hypothesis was true  
3.  In order to isolate the effect of cortical plasticity from potential pathological 
changes that may occur in the visual system in disseminated disease, patients 
with ON and a normal MRI are examined separately from those with a diagnosis 
of MS. 
Methodology  
Subjects 
Patients presenting with unilateral typical acute ON, as determined by a neuro-
ophthalmologist or neurologist, with no previous history of inflammatory demyelinating 
episodes were enrolled.  
Patients with atypical presentation, clinical involvement of the other eye or other 
ophthalmic conditions that could affect the mfVEP measurements were excluded.  
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Patients had brain and spine MRI within two weeks of the ON attack and at least one 
follow up MRI scan within the next 12 months. A diagnosis of MS was made by a 
neurology consultant based on the revised McDonald Criteria for multiple sclerosis 
(88).  
ON patients were analysed as one group and then divided retrospectively on the basis of 
MS diagnosis into two subgroups:   
1. ON with low risk of developing MS (LR) – patients with normal MRI (no 
inflammatory demyelinating lesions in brain or spine) for the first 12 months after the 
attack 
2. MS group – ON patients with brain or spine inflammatory demyelinating lesions on 
MRI who were later diagnosed with MS 
3. Eight age-and-gender-matched controls were enrolled for comparison 
All participants underwent visual acuity testing and ophthalmic evaluation. ON patients 
were tested with mfVEP at three and 12 months after the attack and controls were tested 
once.  
The University of Sydney Ethics Committee approved the study (protocol no. 
2013/106) and all procedures adhered to the tenets of the Declaration of Helsinki with 
informed consent obtained from all participants. 
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MfVEP recording and analysis  
MfVEP testing was performed as described in the methodology section in chapter two. 
Raw data were exported into Microsoft Excel format for analysis. Good SNR was 
calculated by dividing amplitude of signal by noise. Noise level was calculated as the 
standard deviation of amplitude between 400 and 800 ms. Only traces with SNR > 2 in 
both eyes at both sessions were included. Traces of 5/32 segments from three inner 
rings (eccentricity from 2 to 10 deg) and 5/24 segments from two outer rings 
(eccentricity between 10 and 24 deg) were randomly selected and analysed at three 
months and 12 months after the attack in both affected and fellow eyes. Five inner 
segments and five outer segments in one randomly selected eye were analysed for 
controls (Fig 4.1). The first and second major peaks between 70 and 200 ms were 
recorded and analysed (Fig 4.2). Since the first and second peak latency of mfVEP is 
more reproducible than the onset of response (62), waveform width was evaluated by 
subtracting the latency of first peak from the second peak.  
 
Fig 4.1: mfVEP traces of the right eye. Five traces from three inner rigs and five traces 
  from outer two rings were selected for analysis 
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Fig 4.2: waveform of mfVEP recording illustrating first peak, second peak and 
waveform width used for analysis 
 
Statistical analysis 
Statistical analysis was performed using SPSS 21.0 software. A paired student t-test was 
used to evaluate latency change between the tests at three months and twelve months. 
One-way ANOVA with post-hoc Bonferroni correction was used to assess difference 
between groups. Spearman rank correlation and linear regression analysis were used to 
determine correlations between mfVEP values. A p-value of 0.05 or less was considered 
statistically significant. 
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4.3 Results  
Demographic and clinical characteristics of participants 
15 acute ON patients were included. Seven patients had normal brain and spine MRI 
and eight patients had brain lesions and were given a diagnosis of MS at a later stage. 
There was no significant difference in age or gender between groups (Table 4.1).  
 A total of 380 traces were analysed (15 patients x 10 segments x 2 tests and 8 controls 
x 10 segments). Vertical channel recording constituted 57% of traces followed by 
horizontal channel with 35%. Right and left oblique channels made up less than 10% of 
total traces. The vertical channel usually has the best recording because the majority of 
visual fibres project to the upper and the lower banks of the sulcus calcarinus (195). 
There was no significant difference between groups in regard to selected channels (p = 
0.66). 
Table 4.1: Demographic and clinical characteristics of the study participants 
 Number of subjects Mean age (years) Male: female ratio 
Controls 8 36±10 3:8 
Total ON patients  15 36±7 1:3 
MS  8 33±2 3:8 
LR 7 38±9 2:7 
p-value   0.9 0.6 
Abbreviations: ON, optic neuritis; MS, multiple sclerosis; HR, high risk; LR low risk 
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Fellow eye latency in optic neuritis patients 
At three months, the mean latency of the first and second peaks was significantly 
delayed in fellow eyes compared to controls (p = 0.002 and 0.004 for first and second 
peak respectively) (Table 4.2). The latency delay of both peaks increased significantly 
at 12 months with the second peak shifting more than the first peak (1.4ms for first peak 
and 2.4ms for second peak, paired t-test p < 0.001 for both peaks).  
Subgroup analysis 
When analysing patients’ data based on their diagnosis of either MS or LR, mfVEP 
traces of LR group showed a small increase of latency of both peaks from three months 
to 12 months (1.6±1.7 ms and 1.7±3 ms). The shift of the first and second peak was 
similar (p = 0.54). However, latency values still remained within the normal range and 
there was no difference in both peaks compared to controls at both time points (Table 
4.2). 
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Table 4.2: latency delay of first and second peaks in fellow eyes compared to controls* 
Fellow 
eye 
1
st
 peak 2
nd
 peak 
 
 3 months p-
value
# 
12 months p-
value
# 
3 months p-
value
# 
12 months p-
value
# 
Total 99.8±11.6 0.002 101.2±11 0.004 145.6±14 0.004 148±14.5 <0.001 
LR 97±8.6 0.8 98.6±8.5 0.2 141.4±11 0.8 143.1±11.5 0.4 
MS 102.2±13.3 <0.001 103.3±13 <0.001 149.2±15 <0.001 152.4±15.4 <0.001 
* Controls had a first peak latency of 95±10 ms and a second peak latency of 140±14 ms. 
# p-value (one-way ANOVA post-Bonferroni correction) compared to controls 
Abbreviations: MS, multiple sclerosis; LR low risk 
 
 
While the shift of first peak between three months and 12months was similar in the MS 
and LR groups (p = 0.62), the second peak demonstrated significantly a larger increase 
in latency (3.2±3 ms, p = 0.016).  
Furthermore, in the MS group both peaks were significantly delayed, compared to 
controls and the LR group (p < 0.02 for both peaks) even at three months after ON, 
which increased further at 12 months (p ≤ 0.01). 
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Correlation between latency delay of ON eyes and latency change of 
both peaks of fellow eyes  
If latency shift is due to cortical adaptation, patients with more latency delay in the ON 
eye will experience more shift delay in the fellow eye. However, correlation between 
the latency delay of ON eyes and latency change of both peaks of fellow eyes was poor 
(Fig 4.3).  
 
Fig. 4.3: left side shows linear regression plot between latency delay of the first peak in 
ON eyes and change in latency delay of the first peak in fellow eyes. The right plot 
shows the latency delay of the second peak in ON eyes and change in latency delay of 
the second peak in fellow eyes. R-squared values and p-values are included 
 
 
 
 
  100 
MfVEP waveform width in fellow eyes 
There was no significant difference between the waveform width of fellow eyes of ON 
patients and controls at three months or 12 months (Table 4.3).  
 
Table 4.3: waveform width of mfVEP at 3 and 12 month in fellow eyes 
Controls  (44.9±8) p value compared to controls  
Waveform width at 3 months 
LR (44.4±9) 0.8 
MS (47±7) 0.2 
Waveform width at 12 months 
LR (44.8±9) 0.9 
MS (49±10) 0.02 
Abbreviations: MS, multiple sclerosis; LR low risk 
 
Group analysis, however, revealed that while waveform width in the isolated ON group 
continued to be comparable to controls, the MS group displayed a significant increase in 
waveform width which was mainly due to a larger shift of the second peak.  
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4.4 Discussion 
In the current study, we evaluated changes in latency of the mfVEP in the fellow eye of 
ON patients between three and 12 months after an acute ON event and confirmed earlier 
reports by demonstrating a significantly longer latency in the fellow eyes of ON patients 
as compared to normal controls (32, 171, 192).   
In the previous chapter we demonstrated a progressive deterioration in latency and 
amplitude of fellow eyes in patients with a high risk of developing MS and in MS-
diagnosed patients, but not in patients with a low risk of developing MS.  Moreover, in 
chapter five, as discussed in the next chapter, we show that latency delay is related to 
OR lesions in MS patients, who never experienced ON, with OR lesions evident in the 
majority of MS patients even at earlier stages of the disease. We also demonstrate that 
there is a significant correlation between latency delay and OR diffusivity indices, 
which provide further evidence linking latency delay with retro-chiasmal inflammatory 
demyelination (185). 
Raz and colleagues suggested that “delayed latencies in the fellow eyes may reflect 
adaptive mechanisms at the cortical level” (181). The authors hypothesised that the 
temporal reorganisation of cortical processing, which is manifested as latency delay of 
the fellow eye, may compensate for the delayed transmission of visual information from 
the ON eye to the cortex. The basis of their theory came from a cross-sectional study of 
ON patients which showed that PVEP of fellow eyes had a wider waveform 
morphology rather than a delay in time-to-start response with a negligible effect of 
retro-chiasmal lesions. However, PVEP can be impaired by waveform 
cancelation/distortion and macular over-representation, due to large field stimulation, 
which means the effect of small peripheral visual pathway defects could be easily 
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missed. Additionally, MS lesions in the OR area are often orientated to venules rather 
than to OR fibres. This decreases the proportion of fibres damaged by a lesion and 
further reduces the likelihood of PVEP detection. 
We hypothesised that the cortical adaptive mechanisms are similar in MS and isolated 
ON patients and will affect the latency of the fellow eye similarly in both groups. In 
addition, the magnitude of the adaptive effect and, therefore, the magnitude of fellow 
eye latency delay should be proportional to the latency disparity between ON and 
fellow eyes.  
Our results, however, demonstrate considerable differences in latency values and in the 
magnitude of its alteration in the fellow eye of MS patients compared to LR subgroup 
during the follow-up period. While the fellow eyes showed significant delays in 
comparison to controls early after the ON attack, which increased even more by 12 
months, this change was driven by the MS group. Thus, latency delay in fellow eyes of 
the LR group at both three months and the follow-up visit was not statistically different 
to latency observed in controls for both peaks. There was, however, a significant delay 
of the first and second peaks in MS patients in comparison to both controls and LR 
patients. 
Therefore, our data suggests that pre-existing demyelinating activity may be responsible 
to a significant degree for the mfVEP latency delay in the fellow eye of the ON patients. 
This is also supported by the fact that the magnitude of the latency change in the fellow 
eye observed during the follow-up period did not correlate with the severity of latency 
delay in the affected eye.  
Furthermore, while a similar increase of both latency peaks between three and 12 
months was observed in LR group, MS patients demonstrated a significantly larger 
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prolongation of the second peak during the follow-up period, resulting in waveform 
widening. The mfVEPs are largely but not entirely generated from striate cortex with 
some extrastriate contribution (29). Since this widening of the waveform was only seen 
in the MS group, it may indicate the evolving character of demyelination in the primary 
visual cortex itself or in higher visual centres, which is related to the nature of the 
disseminated disease, rather than cortical plasticity. 
 In conclusion, while there was a slight mfVEP latency change between three and 12 
months in the fellow eyes of ON patients with a low risk of MS which might support 
the hypothesis of cortical adaptation as the mechanism of its delay, the mfVEP latencies 
remained within the normal range. The significant mfVEP latency delay in the fellow 
eyes of MS patients and the change over time compared to the LR patients and controls 
supports the assumption that the changes are due to subclinical demyelination in the 
visual pathway outside of the affected optic nerve and is reflective of the burden of 
disease in MS patients rather than adaptation.  
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Chapter five: The relationship of mfVEP latency delay with 
optic radiation inflammatory demyelinating lesions and 
diffusion tensor indices changes in non-optic neuritis eyes of 
MS patients 
 
(The results of this chapter have been published in Investigative Ophthalmology & 
Visual Science 55.6 (2014): 3758-3764) 
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5.0 Overview 
As discussed in chapters three and four, significant latency delay was observed in the 
fellow eyes of ON patients. Since latency delay was mainly driven by the patients who 
later converted to MS, we have suggested that this latency delay may be a result of MS-
related subclinical retro-chiasmal inflammatory demyelination. The focus of this 
chapter is to assess the relationship between latency changes and markers of retro-
chiasmal damage in order to evaluate the potential role of mfVEP latency as a measure 
of retro-chiasmal lesions in MS patients. The first section of this chapter includes a brief 
literature review on VEP changes in non-optic neuritis eyes of MS patients and an 
overview of MRI and diffusion tensor indices (DTI) acquisition and available analysis 
methods. A brief description of DTI changes in MS patients will also be included. The 
second section describes the objectives and methodology used in the current study. The 
third section reports results of data analysis and explores potential correlation between 
the structural and functional parameters included. In the last section, the main results of 
the study are discussed and their implications on the potential role of mfVEP latency as 
a marker for retro-chiasmal demyelination are considered.  
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5.1 Introduction   
VEP assessment of non-optic neuritis eyes (NON) in MS 
In the current study the focus is shifted to mfVEP changes in MS patients with no 
history of ON. The visual pathway is frequently affected in patients with MS. Although 
the optic nerve is most commonly involved either early at presentation or during the 
disease course, significant VEP latency delay has also been reported in a large 
proportion of MS patients with no history of optic neuritis (37, 180, 190, 191) 
The source of this latency delay is still debatable. It has been suggested that VEP delay 
in NON eyes of MS patients may be caused by subclinical optic nerve involvement 
(191), chiasmal spread of inflammation from the optic neuritis side (196), subclinical 
retro-chiasmal inflammatory demyelination, and/or cortical adaptation (176, 181).  
Latency delay of the mfVEP in MS patients without a history of ON in either eye was 
recently reported (197).  A possible retro-chiasmal origin was suggested due to the 
binocular nature of the delay and the fact that VEP response is generated at the level of 
the primary visual cortex and, therefore, possibly influenced by demyelinating lesions 
along the entire visual pathway. 
MS is known to affect the posterior visual pathway. Lesions of the optic tract are rare 
and tend to be clinically apparent (182, 198). On the other hand, OR lesions are very 
common (184, 199, 200). Autopsy studies as well as MRI studies have reported OR 
lesions in up to 70-80% of ON and MS patients (184, 201). The orientation of MS 
lesions is often directed to venules rather than to OR fibres, which decreases the 
proportion of fibres damaged by a lesion and reduces the likelihood of symptomatic 
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visual field defect. Less than 9% of participants in ONTT had an evidence of retro-
chiasmal visual field defects (139, 202).  
Previous studies have failed to find a relationship between OR lesions and VEP latency 
(43, 184). Two main factors may have contributed to this lack of correlation: the 
limitation of conventional VEP to detect small and peripheral field defects, which has 
been discussed in chapter two, and the degree of accuracy of MRI methods of lesion 
identification and optic radiation localisation.  
Until recently studies of OR lesions in vivo were hampered by the observation that optic 
radiation fibres are undistinguishable from the surrounding white matter. However, new 
technological advances in MRI have improved the ability to distinguish the optic tract 
and OR from the surrounding white matter more accurately. 
A brief background on MRI techniques and findings in MS are discussed next. 
MRI background  
In the mid-1940s, Felix Bloch, from Stanford University, and Edward Purcell, from 
Harvard University, revealed that magnetic fields and radio waves cause atoms to emit 
tiny radio signals (203). Both were awarded a Nobel Prize for their work. Years later, 
Paul Lauterbur, a Professor of Chemistry at the State University of New York moved 
science from the single dimension of nuclear magnetic resonance images to two 
dimensional spatial orientation which is considered the foundation of MRI (203). Peter 
Mansfield demonstrated how the signals could be mathematically analysed, which made 
it possible to develop a useful imaging technique (204). During the 1970s, Raymond 
Damadian, a physician and scientist, developed the basis for using magnetic resonance 
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imaging in medical diagnosis (203). Since then, the medical use of the technology has 
advanced rapidly.  
At present, MRI is the method of choice when evaluating CNS tissue pathology. It 
provides a superior image quality compared to computed tomography (CT) due to the 
lack of bony structure artefacts and the absence of ionising radiation.  
Different image contrast is achieved by changing pulse sequences and image 
parameters. The main two basic pulse sequences in MRI are T1 and T2. Their signal 
intensity depends on specific tissue characteristics and brain pathology. 
As with any other tests, MRI has some limitations including longer scanning time and 
motion artefacts. In addition, MRI is contraindicated in patients with cardiac 
pacemakers, cochlear implants, ferromagnetic aneurysm clips, and metallic foreign 
bodies in their eyes.  
MRI and MS 
MS is characterised by the presence of pathological inflammatory demyelinating lesions 
called plaques found in brain tissue and the spinal cord. Lesions are typically distributed 
along the corpus callosum, juxtacortical, and temporal white matter. They affect white 
as well as grey matter and are usually located perpendicular to the ventricles.     
T1-weighted images 
MS lesions may appear hypointense on T1 (Fig 5.1a). Chronic hypointensities, also 
known as “black holes”, have been suggested as signs of irreversible axonal loss and 
tissue destruction (205) and they have been linked to worsening Expanded Disability 
Status Scores (206, 207). In addition, gadolinium can be used to enhance lesions on T1 
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images and to evaluate BBB disruption during active inflammation. The number of 
enhanced lesions was found to have a moderate ability to predict the relapse rate in MS 
(208). 
T2 fluid-attenuated inversion recovery (FLAIR) 
MS lesions appear as hyper-intense foci on T2-weighted FLAIR images (Fig 5.1b). T2-
FLAIR is widely used in MS imaging. In this technique CSF signalling is suppressed to 
differentiate bright lesions commonly found in the periventricular area from bright CSF 
signals, which results in improvement in lesion detection and follow-up (209).  
 
 
Fig 5.1: (a) T1-weighted image of an MS patient with a hypointense lesion (black hole) 
shown with a white arrow. (b) FLAIR T2-weighted image of an MS patients with 
multiple hyperintense foci (one of them shown with a white arrow). Both images are 
from patients that have participated in research that is part of this thesis 
 
Clinical disability was found to correlate better with lesion load on T1 images compared 
to lesion load on T2 images. This is possibly because lesions on T2 images represent 
temporary demyelination, inflammation or oedema rather than permanent axonal loss. 
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This disproportion between T2 findings and clinical disability was referred to as clinic-
radiological paradox and it was therefore, recommended to consider several outcome 
measures such as brain atrophy, spinal cord involvement and masking effect of cortical 
adaptation in evaluating patients to overcome this inconsistency (210). 
While brain atrophy is evident in the late stages of MS, subtle atrophy is increasingly 
recognised early in the disease process especially with improved image quality and 
advanced image processing (211, 212). Furthermore, studies have shown that general 
brain atrophy rate and atrophy in particular areas such as the corpus callosum are 
significant predictors of subsequent disability (213, 214).  
Principles of diffusion tensor images  
One of the recent MRI developments is diffusion-weighted imaging (DWI), which is 
created using the thermal agitation of random movements of water molecules, known as 
Brownian motion. Molecular diffusion in tissues occurs inside, outside and around 
cellular structures and interacts with the cellular environment including many 
microscopic structures such as fibres and membranes.  
One of the early attempts to create and utilise DWI in humans was by Le Bihan, Basser 
and colleagues in the early 1990s (215, 216). They used pulsed magnetic field gradients 
included in a standard spin echo sequence to measure an apparent diffusion coefficient 
(ADC) in normal and pathological brain diffusion images. Diffusion MRI has rapidly 
advanced since then and has been applied to investigate a variety of diseases including 
stroke, epilepsy and MS. 
Diffusion tensor imaging (DTI) is an extension of DWI, which measures the signal 
attenuation from water diffusion to create a three-dimensional map to assess the 
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structural integrity of tissues (217). In contrast to DWI, which uses only the average of 
diffusivity, three diffusion directions can be measured in DTI based on their orientation 
and are referred to as eigenvectors (Fig 5.2).  
 
 
Fig 5.2: An illustration of diffusion eigenvalues represented with diffusion ellipsoid. λ1 
represents the main eigenvector. λ2 and λ3 are two eigenvectors perpendicular to λ1 
 
The largest eigenvalue (λ1) reflects the diffusion parallel to the white matter fibre 
bundle known as axial diffusivity (AD), the average of two eigenvectors perpendicular 
to the axonal fibres (λ2 and λ3) known as radial diffusivity (RD). The average of all 
three eigenvalues, so-called mean diffusivity (MD), is a measure of diffusion that is 
independent of the orientation of structures (218). Therefore, greater MD values imply 
more isotropic diffusion. The fourth parameter measured in DTI is fractional anisotropy 
(FA), which is calculated based on the equation:   
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FA has a value between 0 and 1. Theoretically, an FA value of 0 means that the 
molecular diffusion is equal in all directions (isotropic). On the other hand, a value of 1 
means that the diffusion occurs only in one axis or direction. Since the white matter is 
composed of well-structured nerve fibres surrounded by myelin, diffusion is relatively 
restricted perpendicular to axons and greater along the fibre tract.  
It is believed that diffusion indices, and RD in particular, represent a measure of MS 
damage since they are severely abnormal within the MS lesions (219). AD has 
associated with axonal injury in animal models as well as in humans, while fractional 
anisotropy (FA) is considered a measure of fibre coherence (220, 221). 
Animal studies have shown that myelin is considered one of the main barriers for water 
diffusion in central and peripheral nerve fibres (222-226). A model of Wallerian 
degeneration in the sciatic nerve of a frog showed an increase in RD and decrease in 
AD due to myelin and axonal degeneration (222).  Optic nerve diffusion measurements 
in a mouse model of retinal ischaemia showed an early decrease of AD due to axonal 
injury followed by an increase in RD in later stages in correspondence with myelin 
degradation (223). In another study with experimental demyelination of the corpus 
callosum in a mouse brain, the extent of RD reflected the severity of demyelination with 
evidence of RD reduction during the process of remyelination (224). Similar DTI 
changes have been reported in humans with an increase in radial diffusivity and a 
reduction in axial diffusivity in degenerated white matter tracts (227). 
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Thus, the integrity of white matter and the microscopic changes during pathological 
processes can be assessed in vivo using DTI. However, the acquisition of DTI and 
interpretation are complex and should be performed with caution (228). 
Methods for DTI analysis 
Several methods have been introduced to evaluate the effect of certain disorders on 
diffusion properties of the CNS. The most common approaches are discussed below. 
Region of interest (ROI) based approach 
In this approach, a geometric shape such as a square or a circle is placed manually 
within the anatomical structure of interest. The DTI indices are then measured from the 
voxels that are included within this area. As the ROI is delineated manually, this 
method is prone to low reproducibility and bias. The datasets of patients can be 
transformed to a certain atlas spate so that a single ROI can be used to delineate the 
structure in all participants (229, 230).  
Tractography approach  
The tractography approach provides the ability to identify white matter bundles and 
gives the opportunity to selectively analyse their diffusion properties.  
It is assumed that the orientation of the largest eigenvector runs parallel to white matter 
tracks in a DTI coloured map. Therefore, a white matter tract can be estimated by 
starting at a specific location, also known as an ROI, then assessing the direction of the 
major eigenvector until reaching another ROI. Tractography algorithms can be divided 
into two main groups: deterministic and probabilistic (231).  Deterministic tractography 
was introduced in the late 1990s (232). The algorithm is based on line propagation of 
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streamline techniques, where the tracking of fibres starts at a pixel or a ROI and 
continues as long as the main diffusion vectors are aligned. Tracing is terminated if 
vector orientation becomes random or has an isotropic diffusion with low FA (231). 
Accordingly, the algorithm only creates one reconstructed trajectory per ROI without 
consideration of branching fibres and may result in premature termination of neural 
tracts. 
The probabilistic tractography algorithm, on the other hand, addresses this limitation by 
considering multiple pathways along the reconstructed trajectories (233). Therefore, 
instead of a distinct trajectory, the probabilistic approach generates potential pathways. 
However, anatomical knowledge is essential in evaluating such pathways as the 
connectivity map may involve unexpected regions of the brain. 
In spite of the promising results in tractography, several limitations of this method 
should be noted and considered during DTI acquisition and analysis. These include 
image artefacts and thermal and physiological fluctuation, which can affect the greatest 
eigenvector estimation and its direction (228). Partial volume averaging between tissues 
in large voxels may result in signal mixing of grey matter, white matter and CSF 
resulting in less accurate measurements (234). Lastly, algorithms based on the major 
eigenvector are still incapable of estimating white matter tracts in regions with crossing 
white matter pathways (235). While DTI technology is still in its infancy, attempts are 
underway on several fronts, including improved data acquisition approaches and 
analysis methodology, to overcome these limitations (236).  
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DTI in MS 
Several studies have highlighted the ability of DTI to detect abnormality in white matter 
affected by lesions and in normal appearing white matter of MS patients (237-244). 
DTI and demyelination  
Myelin contributes significantly to the anisotropic nature of the diffusion in white 
matter fibres as it limits diffusion of water within the axons. It has been suggested that 
myelin destruction therefore disturbs the structural barrier and increases the diffusion 
perpendicular to white matter fibres, which as a result increases RD and MD 
measurements and reduces FA (158, 224, 238, 242, 245). Klawiter and colleagues 
showed a significant correlation between RD and demyelination severity in acute MS 
lesions of the spinal cord using autopsy material (246). Fox and colleagues reported a 
reduction of RD in active MS lesions after the use of natalizumab, a neuro-protective 
agent, and inferred that the observed change after treatment may signify a process of 
remyelination (247). 
DTI and inflammation   
There is limited work on the specific effect of inflammation on DTI measurements, but 
a few studies have suggested that AD reduction may be attributed to axonal damage 
(225, 240). Tievsky and colleagues examined the difference of ADC and FA 
measurements in acute and chronic MS lesions and showed that there is increased ADC 
and decreased FA in acute lesions (244). Acute inflammatory changes can result in 
increased endothelial permeability, inflammatory cell migration and oedema, which 
result in a reduction of tissue anisotropy and an increase in mean diffusivity. Werring 
and colleagues compared MD in acute and chronic MS lesions. They reported a higher 
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MD in acute lesions compared to chronic ones, which reflects the acute inflammatory 
status and oedema, while chronic lesions demonstrated a large range of MD, reflecting 
possible pathologic heterogeneity including gliosis, axonal loss and persistent 
demyelination. A lower FA was also observed in T1 hypointense lesions compared with 
T1 isointense lesions and was related to presumed axonal loss (240). 
DTI and clinical disability in MS 
Whether DTI measurements differ based on MS subtypes is still uncertain. Scanderbeg 
and colleagues reported higher diffusivity in SPMS as compared to RRMS (248). Their 
findings were in agreement with another study that reported higher abnormal DTI 
values in whole brain MD in SPMS compared with RRMS (249). A significant 
correlation between DTI measurements and lesion load was observed in patients with 
RRMS and SPMS, but not PPMS (250). This may be explained by the atypical MRI 
features in PPMS and the more severe clinical disability in this subgroup.  
Several studies reported a moderate to strong correlation between different DTI indices 
and clinical disability in MS patients (242, 248, 251). Ciccarelli and colleagues reported 
a stronger correlation between DTI measurements and clinical disability in SPMS 
compared to RRMS (251). FA has a negative correlation with Expanded Disability 
Status Scale, which was also more severe in advanced stages (242). A correlation 
between DTI of the optic nerves and several visual parameters including visual acuity, 
VEP and RNFL thickness has been recently reported (252, 253).    
Therefore, the evidence from the literature suggests that DTI is a useful tool in 
assessing the microstructural integrity of white matter tracts and was therefore included 
in the current study to explore the relationship between mfVEP latency and retro-
chiasmal damage of the visual pathway in MS patients.  
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5. 2 Aims and methodology  
 The purpose of the study  
4. To evaluate the mfVEP latency in MS patients with no previous history of ON 
and to compare it with the mfVEP latency of age-and-gender matched controls.  
5. To examine the relationship between mfVEP latency delay and optic radiation 
lesions identified on T1 and FLAIR T2-wieghted MRI. 
6. To assess the correlation between mfVEP latency delay and optic radiation DTI 
indices. 
Rational of the study  
Significant latency delay has been reported in MS patients with no history of optic 
neuritis (37, 180, 191). It has been suggested that VEP delay in those eyes is caused by 
subclinical optic nerve involvement (191) or chiasmal spread of inflammation from the 
optic neuritis side, if one eye has been affected (193). However, based on the binocular 
nature of the delay and the fact that VEP response is generated at the level of the 
primary visual cortex, a possible retro-chiasmal origin was suggested (197, 254). The 
current study was conducted to test this hypothesis by evaluating the relationship 
between mfVEP latency delay, optic radiation inflammatory demyelinating lesions and 
DTI changes in NON eyes of MS patients. 
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Methodology  
Subjects 
Consecutive patients with RRMS with no history of clinical ON, at least in one eye 
were enrolled from MS clinic at Brain and mind institute, Royal North Shore Hospital 
and St. Vincent’s Hospital together with 25 age- and sex-matched healthy controls. 
Pre-enrolment assessment 
All participants were asked about previous signs and symptoms of ON and underwent 
visual acuity testing, full ophthalmic evaluation including slit lamp examination as well 
as optic disc evaluation. Patients matching the study inclusion criteria were offered to 
be part of the study.  
Patients with other systemic or ocular diseases that could confound results such as 
retinal or optic nerve diseases were excluded.  
All procedures adhered to the tenets of the Declaration of Helsinki.  Ethical approval 
was obtained from the University of Sydney Ethics Committee (protocol no. 2013/106). 
Written Informed consent was obtained from all participants after the study Procedures, 
time involved and potential risks were discussed.  
The inclusion criteria were:     
 Adult (>16 years old) 
 RRMS diagnosed by a neurology consultant  
 No history of ON in at least one eye  
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The exclusion criteria: 
 Presence of eye disease that could interfere with the mfVEP measurements such 
as optic neuropathies, glaucoma, dense cataract, retinal detachment or 
amblyopia.  
  Mental or physical disabilities that may interfere with performing reliable tests.  
 Inability to fixate at a point from a distance of 30 cm due to poor vision (usually 
if best corrected vision is less than 6/60) 
All participants were tested using brain and spine MRI and mfVEP once.  
Study procedures  
MfVEP recording and analysis  
MfVEP testing was performed with Accumap (ObjectiVision Pty. Ltd., Sydney, 
Australia) as described in the methodology section of chapter two. One eye was 
randomly selected for MS patients with no previous ON, while the NON eye was tested 
in patients with a documented previous ON. Averaged latency values from all segments 
of the visual field were used for latency analysis.  
MRI recording and analysis  
MRI protocol  
MRI data was collected using a 3.0 Tesla GE MR750 scanner (GE Healthcare, Little 
Chalfont, UK). Three sequences were implemented: Sagittal 3D T1 (GE BRAVO 
sequence, FOV 256mm, slice thickness 1 mm, Discovery MR750, TE 2.7 ms, TR 7.2 
ms, Flip angle 12°, pixel spacing 1mm); FLAIR CUBE (GE CUBE T2 FLAIR 
sequence, FOV 240mm, slice thickness 1.2mm, acquisition matrix (Freq.× Phase) 
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256×244, TE 163ms, TR 8000ms, Flip angle 90°, Pixel spacing 0.47 mm); and DTI 
pulse sequence (Spin Echo, 64 directions, FOV 256 mm, acquisition matrix (Freq.× 
Phase) 128 ×128, slice thickness 2 mm, TE 83ms, TR 8325 ms).  
Tractography  
Probabilistic tractography using the ConTrack algorithm, as described by Sherbondy 
and colleagues (255), was used to reconstruct the optic tract and OR fibers. The 
ConTrack algorithm was chosen because it uses the probabilistic tractography technique 
and therefore has the ability to overcome some of the limitations of deterministic 
algorithms in detecting white matter pathways (as discussed in the previous section of 
this chapter). Additionally, the ConTrack algorithm appears to be superior to other 
probabilistic algorithms in detecting Meyer’s loop as well as direct optic radiation 
pathways (255, 256).  
 DTI and FLAIR T2 images were co-registered to a high resolution T1 structural image.  
Prior to the reconstruction of OR, two ROIs were determined. The first was the LGN on 
both sides. To identify the LGN, the optic chiasm was located from the FA map using 
deterministic tractography. A 10 mm ROI was placed on the chiasm and was used for 
seeding of the deterministic algorithm. The optic tract was then followed to the LGN 
area (around 4 mm tract). The position of the LGN was determined and a ROI (diameter 
7 mm) was placed at the end of the tract on the posterior lateral area of the thalamus on 
both sides. The ROI size was chosen to ensure that the whole LGN in included as the 
size of LGN varies among individuals (257). 
The second ROI was the calcarine sulcus, which was segmented manually in each 
hemisphere using ITK-SNAP software (258). Probabilistic tractography software 
(ConTrack) was run between the first ROI (LGN) and the second ROI (calcarine sulcus) 
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to reconstruct the optic radiation. 70,000 fibres were collected initially and the 30,000 
best fibres were selected by scoring algorithm. Optic radiation fibres were then 
manually cleaned using Quench software. 
Identification of MS lesions  
MS lesions were identified on co-registered FLAIR T2 and T1 images and segmented 
semi-automatically using ITK-SNAP software. Lesions were then intersected with optic 
radiation fibres to calculate their volume within and outside of the optic radiation (Fig 
5.3). An averaged (between the left and right side) lesion volume was used for analysis. 
DTI indices (FA, MD, AD, and RD) were calculated along the OR (between ROI 1 and 
ROI 2). 
 
Fig 5.3: (a) 3-D tractographic image demonstrates optic tract fibres in green and optic 
radiation in yellow. (b) Lesions (in red) were intersected with visual pathway fibres 
  
A 
B 
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Statistical analysis 
Statistical analysis was performed using SPSS 21.0 (SPSS, Chicago, IL, USA). The 
examined variables followed a normal distribution, Spearman rank correlation and 
linear regression analysis with adjustment for confounding factors were used to 
determine correlations between variables. The entire data were analysed as one group. 
Then, since the fellow eyes of ON patients may potentially be affected by chiasmal 
spill-over of inflammation from the ON eye, participants were separated to two groups: 
a group of fellow eyes of optic neuritis patients (“ON group”) and a group of study eyes 
of patients who never experienced ON in either eye (“NON group”).  
Paired or unpaired student t-test or ANOVA were used when suitable and a p-value of 
0.05 or less was considered statistically significant. 
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5.3 Results  
Demographic and clinical characteristics of participants 
Fifty-nine MS patients were enrolled. Two participants with chiasmal involvement were 
excluded. Twenty-seven patients had a previous history of optic neuritis in one eye 
while 30 patients had no previous history of optic neuritis. One eye was randomly 
selected for patients without a history of ON, while the non-optic neuritis eye was used 
in patients with a history of previous ON. These two MS subgroups were analysed 
together and then individually for correlations. Demographics are presented in Table 
5.1. 
Table 5.1: Demographic and clinical characteristics of participants: 
 Number 
of 
subjects 
Age Female: male 
ratio 
Disease 
duration 
(years) 
Latency of 
mfVEP 
Controls 25 39.9±10.2 19:6 (76%)  149.3±5.1 
MS patients 57 40.8±11.9 42:15 (74%) 4.68±3  161.2±9 
p-value  0.7 0.8  <0.0001 
Abbreviations: MS, multiple sclerosis 
 
The average mfVEP latency of non-optic neuritis eyes in the entire MS cohort was 
significantly delayed compared to healthy controls (p < 0.0001, Student’s t-test, Table 
5.1). 
 No lesions were identified in the optic tract in any of the patients; however, 77% 
(44/57) of patients had OR lesions demonstrated on T2 FLAIR images. The lesion 
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volume varied between 24 mm
3 
and 4512 mm
3
 and constituted about 10% of total brain 
lesion volume. T1 OR lesions were detected in 72% (41/57) of patients with lesion 
volume varying between 20 mm
3 
and 3060 mm
3
. T1 lesion volume also represented 
about 10% of total T1 brain lesion volume. T1 lesion volume was significantly lower 
compared to T2 FLAIR both within and outside of the OR (p = 0.001 and < 0.0001 
respectively, Table 5.2).  
Table 5.2: lesion volume/mm³ on T2 FLAIR and T1-weighted images  
 T2 FLAIR T1-weighted  p-value* 
OR lesion volume (mm
3
) 745±144 525±100 0.001 
Lesion volume outside OR (mm
3
) 7727±1064 5194±744 <0.00001 
*p-value is the statistical difference between T2 FLAIR and T1 lesion volume/mm³. 
Abbreviations: OR, optic radiation 
 
 
Correlation between mfVEP latency and lesion volume 
Entire study cohort 
OR lesion volume was strongly associated with total brain lesion volume for both T2 
FLAIR and T1 images (r = 0.85, p < 0.001 and r = 0.89, p < 0.001 respectively). 
Therefore, in order to examine tract-specific relationships between mfVEP latency 
delay and OR lesion volume, correlation between the two was corrected for lesion 
volume outside of OR. In addition, correlation was also adjusted for age, gender and 
disease duration. Partial correlation demonstrated a significant positive association 
between mfVEP latency and optic radiation T2 FLAIR lesion load (Table 5.3). An 
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example is presented in Fig 5.4. There was also a significant (albeit on a lesser scale) 
correlation between mfVEP latency and OR T1 lesion load. 
 
Table 5.3: mfVEP latency correlation with diffusion indices and OR lesion volume 
after adjusting for age, gender, disease duration, and brain lesion outside OR 
 Entire cohort  Fellow eye of ON 
patients 
Study eye in patients 
without previous 
history of ON  
 Correlation p-value Correlation p-value Correlation p-value 
T2 OR lesion 
volume 
0.50 < 0.001 0.30 0.2 
 
0.69 < 0.001 
T1 OR lesion 
volume 
0.31 0.03 0.07 0.8 
 
0.53 0.005 
FA -0.34 0.016 -0.3 0.2 -0.34 0.07 
MD 0.5 < 0.001 0.38 0.1 0.58 0.001 
AD 0.42 0.003 0.20 0.3 0.50 0.006 
RD 0.48 0.001 0.38 0.1 0.56 0.002 
Abbreviations: OR, optic radiation; FA, fractional anisotropy; MD, mean diffusivity; 
AD, axial diffusivity; RD, radial diffusivity. 
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Fig 5.4: MS patient with no history of optic neuritis showing (a) mfVEP latency delay 
(darker zones) and (b) left optic radiation lesions (in red, with tract fibres in yellow) 
with corresponding increase of radial diffusivity. 
 
 
Fig 5.5: partial regression plots for the entire cohort of study participants and sub-group 
analysis according to the presence or absence of previous ON in fellow eyes.  
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Group analysis 
Participants were separated into two groups, an ON group and NON group to assess the 
potential effect of ON on the observed correlation. The groups demonstrated similar 
ages, female-to-male ratio and disease duration. Latency of the mfVEP in both groups 
was significantly delayed, but there was no difference between the groups (p = 0.8, 
Student’s t-test). The total lesion volumes and optic radiation lesion volumes for both 
T1 and T2 FLAIR were also similar between the two groups (Table 5.4). Correlations 
between mfVEP latency and OR lesion volume were performed for each group 
separately. While in the ON group the correlation between mfVEP latency of the fellow 
eyes and OR T2 FLAIR lesions volume lost significance, the correlation for the study 
eye in the NON group was increased considerably compared to the entire cohort. A 
similar result was observed for T1 lesions: there was a loss of significance for the 
fellow eyes in the ON group but there was an increased correlation for the study eyes in 
the NON group (Table 5.3). Noticeably, even for the study eyes of NON-patients, the 
correlation of T1 lesion volume with mfVEP latency was less strong compared to T2 
FLAIR lesion volume.  
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Table5.4: Demographic and clinical characteristics of MS participants with and without history of ON in fellow eye 
 No. Age 
(years) 
Female: male 
ratio 
Disease 
duration 
(years) 
Latency of 
mfVEP 
T2 OR lesion 
volume (mm
3
) 
T2 total lesion 
volume (mm3) 
T1 OR lesion 
volume (mm3) 
T1 total lesion 
volume (mm3) 
Fellow eye of 
ON patients 
27 40.1±11.3 21: 6 (76%) 4.71±3.1 161.6±8.2 874 
 
9327 
 
603 
 
6508 
 
Study eye of 
NON patients 
30 41.3±12.4 21: 9 (72%) 4.66±3.0 160.0±9.7 653 
 
7988 417 4853 
p-value  0.7 0.8 0.9 0.8 0.5 0.6 0.4 0.3 
Abbreviations: MS, multiple sclerosis; ON, optic neuritis; NON, non-optic neuritis  
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Correlation between mfVEP latency and OR DTI metrics 
Entire study cohort 
There was a significant and very similar increase of axial and radial diffusivity in the 
entire patient cohort compared to normal controls. As a result, MD (i.e. diffusion in all 
directions) also increased, while FA (relative directional diffusivity) remained stable 
(Table 5.5). 
Table 5.5: Optic radiation DTI characteristics of participants   
 MS patients Controls p-value 
FA 0.49±0.04 0.50±0.02 0.16 
MD 0.88±0.07 0.82±0.03 <0.0001 
AD 1.4±0.07 1.32±0.05 <0.0001 
RD 0.62±0.07 0.56±0.04 <0.0001 
Abbreviations: DTI, Diffusion tensor images; FA, fractional anisotropy; MD, mean 
diffusivity; AD, axial diffusivity; RD, radial diffusivity. 
 
All four indices were significantly correlated with mfVEP latency. RD and MD 
demonstrated strongest association followed by AD. FA displayed the weakest 
correlation with latency (Table 5.3). 
Group analysis 
Group analysis of the relationship between the DTI indices and mfVEP latency 
demonstrated a behaviour similar to the one described above for the lesion volume: 
correlation increased for the NON group, but was insignificant for the fellow eyes of 
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ON patients (Table 5.3 and Fig 5.5).  
Except for FA, all DTI indices in both groups remained significantly different from 
normal controls (ANOVA, Tukey post-hoc test, p < 0.0001). However, diffusivity 
changes in the fellow eyes of ON patients displayed larger deviation from normal 
controls compared to the study eyes of NON patients, particularly in RD, for which the 
difference between the two groups demonstrated a tendency for significance (0.64±0.01 
vs. 0.6±0.01for the fellow eyes of ON and NON patients respectively, ANOVA, Tukey 
post-hoc test, p = 0.06). 
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5.4 Discussion 
In this study we analysed the relationship between latency of the mfVEP and structural 
markers of primary MS-related damage in the posterior visual pathway. We 
hypothesised that the latency delay of mfVEP in the eyes of MS patients without 
previous ON may be caused by retro-chiasmal demyelinating lesions. This assumption 
was based on the binocular nature of the mfVEP latency delay in MS patients without 
ON in either eye, which has been reported previously (197).  
The findings of the current study support this hypothesis. Thus, in addition to 
confirming extensive latency delays in NON eyes compared to normal controls, we 
found a significant association between latency of the mfVEP and lesion volume of the 
optic radiation as determined by both T1 and T2 FLAIR MRI. Since lesion volume 
within the OR correlates highly with volume of the lesions in the rest of the brain, 
correction for non-optic radiation white matter lesion volume was necessary to 
determine a tract-specific relationship. This correction, as well as adjustment for age, 
sex and disease duration had minimal effect on the revealed association. 
Lesion volume determined on T2 FLAIR sequence was generally larger and its volume 
within the OR demonstrated a higher degree of correlation with the mfVEP latency 
delay than T1 lesion volume. This is possibly related to the fact that, while both T1 and 
T2 lesions have low histopathological specificity, chronic T1-weighted lesions (“black 
holes”) are associated with severe tissue destruction and axonal loss, while T2 lesions 
are more linked to demyelination (205, 259, 260).  
Another novel finding of this study is the demonstration of a significant correlation 
between the latency of the mfVEP and OR diffusivity indices. Changes of DTI indices 
  132 
in the OR of MS patents have been reported previously (261, 262). Reich and 
colleagues demonstrated significant abnormality in all DTI indices in the OR of MS 
patients (lower FA and higher MD, AD and RD values) (262). Similar alterations of OR 
DTI indices in MS patients were recently confirmed by Rocca and colleagues (261). 
More importantly, both studies also demonstrated a strong association between DTI 
changes, particularly RD, with the presence of OR lesions. Therefore, correlation 
between latency delay of the mfVEP and DTI indices provides further evidence linking 
the mfVEP delay with retro-geniculate inflammatory demyelination.  
An important observation is also related to the sub-analysis based on the history of ON: 
patients without previous ON in either eye demonstrated considerably stronger (and 
more significant) correlation between mfVEP latency and OR lesion load compared to 
the entire cohort. On the other hand, when only the fellow eyes of ON patients were 
analysed, the correlation between mfVEP latency and OR lesions became insignificant. 
This trend was similar for all lesional measures including T2 and T1 lesions and DTI 
indices. Since both groups have similar demographics and disease burden, it is likely 
that the presence of ON may mask the relationship between mfVEP latency and OR 
lesions in the fellow eye.  
The effect of ON on the OR is still unclear with a limited number of studies that 
addressed the impact of optic neuritis on the posterior visual pathway (183, 262, 263). 
Evangelou and colleagues suggested a process of retrograde, anterograde or trans-
synaptic degeneration as a mechanism of neuronal atrophy in the visual pathway. 
Ciccarelli and colleagues studied the effect of ON on the OR using fast marching 
tractography and DTI and reported subtle anatomical and functional changes in the OR. 
The effect of ON on the posterior visual pathway, which may result in significant 
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alteration of OR diffusivity, could potentially affect the correlation between mfVEP 
latency and DTI metrics (262, 263). 
In addition, a potential chiasmal spill-over of the inflammatory demyelination from the 
ON eye, even in a few cases, may dramatically change mfVEP latency, but would not 
have any effect on OR lesions. It has also been suggested that adaptive cortical 
mechanism may contribute to the VEP latency delay in the fellow eyes of ON patients 
(particularly to the late VEP waves, which are measured in this study). It was proposed 
that the delay in cortical processing of visual information from the unaffected eye may 
compensate for the slowdown of visual input from the affected eye caused by 
demyelination of the optic nerve (181).  
There are several limitations in this study. Firstly, magnetization transfer imaging 
(MTI) has not been used. However, while MTI may potentially help in lesion 
identification, we believe that combination of T2 FLAIR and DTI-reconstructed optic 
radiation allowed us to detect and measure the majority of the lesions in the posterior 
visual pathway.  
Secondly, cortical damage, which may potentially affect the OR, has not been analysed. 
However, current detectability of cortical lesions (even using most sensitive double 
inversion recovery sequence) is very poor. In addition, DTI has not been shown to 
identify cortical damage of the occipital brain.  
Thirdly, a potential effect of cortical plasticity and sub-clinical ON on the correlation 
between the latency of the mfVEP and lesions of the posterior visual pathway has not 
been investigated. In addition, severe damage to axons in some lesions may result in 
axonal loss and a decline in mfVEP amplitude, rather than latency delay, which may 
also have an impact on correlation.  
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In conclusion, the current study evaluated the relationship between mfVEP latency and 
structural changes of the OR on MRI in MS patients. The result of this study supports 
our hypothesis that optic radiation lesions are responsible for latency prolongation in 
NON eyes of MS patients. Previous ON, however, may have a significant contribution 
to latency delay even in the fellow eye. Care should therefore be taken to adjust for this 
factor if mfVEP latency is to be used as a marker of demyelination in the posterior 
visual pathway. 
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            Chapter six: conclusions and future directions 
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6.0 Overview 
This chapter summarises the main findings and conclusions of this thesis. The 
contribution of mfVEP in the assessment of damage and recovery of the visual pathway 
is highlighted and directions for future research are identified. 
6.1 General discussion and conclusions  
MfVEP provides an objective functional measure of the integrity of the visual pathway. 
The results of this thesis shed a new light on changes in the mfVEP caused by visual 
pathway lesions. In chapter two, full-field PVEP limitation in detecting focal visual 
field defects was demonstrated in a group of patients with different visual pathway 
disorders. Our findings showed that mfVEP offers a greater resolution of visual 
pathway function including peripheral visual field fibres and may therefore provide a 
more accurate assessment of visual defects when compared with conventional full-field 
PVEP. 
Chapter three evaluated the evolution of mfVEP following acute inflammation of the 
optic nerve through a longitudinal analysis of mfVEP parameters of affected and fellow 
eyes in a large cohort of patients during the first 12 months after acute ON. The findings 
confirm previous reports of grossly abnormal amplitude and latency of affected eyes at 
early stages of ON (21, 176). Both amplitude and latency of the mfVEP improve 
considerably during the first year after acute ON with the majority of the recovery 
occurring within the first three months. This pattern of recovery is also in line with 
previous studies, which have demonstrated a rapid improvement of vision within the 
early post-acute period (33, 79, 176). Our results also demonstrated significant residual 
latency delay even 12 months after acute ON. This chronically persisting latency delay 
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remains the major hallmark of previous ON. We argued that more severe involvement 
of ON eyes in MS patients (and to a lesser extent in patients at high risk of developing 
MS) is probably due to a retro-chiasmal inflammatory demyelination, which occurs  
frequently in MS and is not related to the difference in remyelination pattern between 
MS and LR groups. This is in line with the observed progressive deterioration of both 
amplitude and latency in the fellow eyes of MS and HR groups and was supported by 
inter-eye asymmetry analysis (which was used to minimise retro-chasmal lesion effect). 
Another key finding presented in this chapter was a demonstration of an early predictive 
power of mfVEP amplitude in post-ON axonal loss suggesting a possible role of this 
measurement as a potential functional surrogate marker in neuro-protective trials. 
In chapter four we took our investigation in regard to the mechanism of latency delay in 
fellow eyes in ON patients a step further by testing the recently proposed hypothesis 
that prolongation of the latency in fellow eyes after ON is an adaptive cortical plasticity 
to compensate for delayed transmission of visual information (181). We evaluated 
mfVEP latency and waveform changes over a one-year period in individual traces from 
mfVEP segments in patients with isolated ON and MS-related ON. Our results, which 
demonstrated significant mfVEP latency delay in the fellow eyes of MS patients early 
after attack and a change in waveform over time compared to the LR patients and 
controls, support the assumption that the observed changes are due to subclinical 
demyelination in the visual pathway outside of the affected optic nerve and a reflection 
of the burden of disease in MS patients. Moreover, while there was slight mfVEP 
latency change between 3 and 12 months in the fellow eyes of ON patients with a low 
risk of MS (this might support the hypothesis of cortical adaptation mechanism), the 
mfVEP latencies remained within normal range. The poor correlation between latency 
delay of ON eyes and latency change of both peaks of fellow eyes also argues against 
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the assumption that latency delay in fellow eyes is a compensation for the delayed 
transmission of the visual information from ON eyes.   
In the last chapter we focused on an evaluation of the relationship between mfVEP 
latency and posterior visual pathway lesions in MS patients. We demonstrated a 
significant association between latency of the mfVEP and lesion volume within the 
posterior visual pathway on both T1 and T2 FLAIR MRI. A potential masking effect of 
previous ON on the correlation between latency delay in the fellow eyes and OR lesions 
was discussed and we suggested that care should be taken to adjust for this factor if 
mfVEP latency is to be used as a marker of demyelination in the posterior visual 
pathway. A novel finding of this chapter is the demonstration of a significant correlation 
between the latency of the mfVEP and OR diffusivity indices, which provides evidence 
linking the mfVEP delay with retro-geniculate inflammatory demyelination.  
6.2 Directions for future research 
MfVEP is a relatively new and evolving technique. Future advances in various aspects 
of mfVEP recording and analysis techniques will certainly improve the reliability and 
the clinical utility of this technique. Recently, promising new software programs have 
been proposed to analyse signal progression in mfVEP with higher accuracy using 
cross-correlation between signals (61, 264). Further studies are needed to verify and 
assess their utility in the clinical setting.  
Combining different tests to evaluate structural and functional integrity of the visual 
pathway in longitudinal studies is an interesting prospect allowing more comprehensive 
assessment of the visual pathway pathology. The strong correlation between mfVEP 
amplitude and long term axonal loss measured by OCT which was demonstrated in 
chapter three suggests a role for mfVEP amplitude as a functional biological marker for 
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axonal loss. This is an area that merits further research. The relationship between 
latency delay and DTI of the optic radiation has not been previously investigated and it 
would be interesting to assess this in a longitudinal study with a larger sample size.  
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